<!DOCTYPE html>
<html lang="en" class="no-js">
    <head>
        <title>Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression | Breast Cancer Research | Full Text</title>

        
    
        
    


        
        
    
    <meta name="journal_id" content='13058'/>
    
    <meta name="dc.title" content='Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression'/>
    
    <meta name="dc.description" content='Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear. Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E2 (PGE2) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on tumor growth. Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. PGE2 released by cancer cells upregulates IDO expression in fibroblasts through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely, fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors inhibit tumor growth in vivo. Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival.'/>
    
    <meta name="dc.source" content='Breast Cancer Research 2014 16:4'/>
    
    <meta name="dc.format" content='text/html'/>
    
    <meta name="dc.publisher" content='BioMed Central'/>
    
    <meta name="dc.date" content='2014-07-25'/>
    
    <meta name="dc.type" content='OriginalPaper'/>
    
    <meta name="dc.language" content='En'/>
    
    <meta name="dc.copyright" content='2014 Chen et al.; licensee BioMed Central; licensee BioMed Central Ltd.'/>
    
    <meta name="dc.rights" content='http://creativecommons.org/licenses/by/4.0'/>
    
    <meta name="dc.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.issn" content='1465-542X'/>
    
    <meta name="prism.publicationName" content='Breast Cancer Research'/>
    
    <meta name="prism.publicationDate" content='2014-07-25'/>
    
    <meta name="prism.volume" content='16'/>
    
    <meta name="prism.number" content='4'/>
    
    <meta name="prism.section" content='OriginalPaper'/>
    
    <meta name="prism.startingPage" content='410'/>
    
    <meta name="prism.copyright" content='2014 Chen et al.; licensee BioMed Central; licensee BioMed Central Ltd.'/>
    
    <meta name="prism.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.url" content='https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0410-1'/>
    
    <meta name="citation_pdf_url" content='https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/s13058-014-0410-1?site=breast-cancer-research.biomedcentral.com'/>
    
    <meta name="citation_abstract_html_url" content='https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0410-1'/>
    
    <meta name="citation_fulltext_html_url" content='https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0410-1'/>
    
    <meta name="citation_journal_title" content='Breast Cancer Research'/>
    
    <meta name="citation_publisher" content='BioMed Central'/>
    
    <meta name="citation_issn" content='1465-542X'/>
    
    <meta name="citation_title" content='Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression'/>
    
    <meta name="citation_volume" content='16'/>
    
    <meta name="citation_issue" content='4'/>
    
    <meta name="citation_date" content='2014/07/25'/>
    
    <meta name="citation_publication_date" content='2014/07/25'/>
    
    <meta name="citation_firstpage" content='410'/>
    
    <meta name="citation_article_type" content='Research article'/>
    
    <meta name="citation_fulltext_world_readable" content=''/>
    
    <meta name="dc.creator" content='Jing-Yi Chen'/>
    
    <meta name="dc.creator" content='Chien-Feng Li'/>
    
    <meta name="dc.creator" content='Cheng-Chin Kuo'/>
    
    <meta name="dc.creator" content='Kelvin K Tsai'/>
    
    <meta name="dc.creator" content='Ming-Feng Hou'/>
    
    <meta name="dc.creator" content='Wen-Chun Hung'/>
    
    <meta name="dc.subject" content='Cancer Research'/>
    
    <meta name="dc.subject" content='Oncology'/>
    
    <meta name="dc.subject" content='Surgical Oncology'/>
    
    <meta name="citation_author" content='Jing-Yi Chen'/>
    
    <meta name="citation_author_institution" content='National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan'/>
    
    <meta name="citation_author" content='Chien-Feng Li'/>
    
    <meta name="citation_author_institution" content='Department of Pathology, Chi-Mei Foundation Medical Center, Tainan, Taiwan'/>
    
    <meta name="citation_author" content='Cheng-Chin Kuo'/>
    
    <meta name="citation_author_institution" content='Institute of Cellular and System Medicine, National Health Research Institutes, Maoli, Taiwan'/>
    
    <meta name="citation_author" content='Kelvin K Tsai'/>
    
    <meta name="citation_author_institution" content='National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan'/>
    
    <meta name="citation_author" content='Ming-Feng Hou'/>
    
    <meta name="citation_author_institution" content='Department of Surgery, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan'/>
    
    <meta name="citation_author_institution" content='Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan'/>
    
    <meta name="citation_author_institution" content='Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan'/>
    
    <meta name="citation_author" content='Wen-Chun Hung'/>
    
    <meta name="citation_author_institution" content='National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan'/>
    
    <meta name="citation_author_institution" content='Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan'/>
    
    <meta name="citation_author_institution" content='Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan'/>
    
    <meta name="citation_reference" content='citation_journal_title=Oncogene; citation_title=The role of cyclooxygenases in inflammation, cancer, and development; citation_author=CS Williams; citation_author=M Mann; citation_author=RN DuBois; citation_volume=18; citation_publication_date=1999; citation_pages=7908-7916; citation_doi=10.1038/sj.onc.1203286; citation_id=CR1;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Gastroenterology; citation_title=Inflammation and colon cancer; citation_author=J Terzic; citation_author=S Grivennikov; citation_author=E Karin; citation_author=M Karin; citation_volume=138; citation_publication_date=2010; citation_pages=2101-2114; citation_doi=10.1053/j.gastro.2010.01.058; citation_id=CR2;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Breast Cancer Res; citation_title=Inflammation and breast cancer: cyclooxygenase/prostaglandin signaling and breast cancer; citation_author=LR Howe; citation_volume=9; citation_publication_date=2007; citation_pages=210; citation_doi=10.1186/bcr1678; citation_id=CR3;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Res; citation_title=Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer; citation_author=A Ristimaki; citation_author=A Sivula; citation_author=J Lundin; citation_author=M Lundin; citation_author=T Salminen; citation_author=C Haglund; citation_author=H Joensuu; citation_author=J Isola; citation_volume=62; citation_publication_date=2002; citation_pages=632-635; citation_id=CR4;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Cancer Res Clin Oncol; citation_title=Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis; citation_author=P Wulfing; citation_author=R Diallo; citation_author=C Muller; citation_author=C Wulfing; citation_author=C Poremba; citation_author=A Heinecke; citation_author=A Rody; citation_author=RR Greb; citation_author=W Bocker; citation_author=L Kiesel; citation_volume=129; citation_publication_date=2003; citation_pages=375-382; citation_doi=10.1007/s00432-003-0459-1; citation_id=CR5;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Clin Cancer Res; citation_title=Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer; citation_author=G Davies; citation_author=J Salter; citation_author=M Hills; citation_author=LA Martin; citation_author=N Sacks; citation_author=M Dowsett; citation_volume=9; citation_publication_date=2003; citation_pages=2651-2656; citation_id=CR6;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Natl Cancer Inst; citation_title=Prospective study of regular aspirin use and the risk of breast cancer; citation_author=KM Egan; citation_author=MJ Stampfer; citation_author=E Giovannucci; citation_author=BA Rosner; citation_author=GA Colditz; citation_volume=88; citation_publication_date=1996; citation_pages=988-993; citation_doi=10.1093/jnci/88.14.988; citation_id=CR7;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Semin Oncol; citation_title=The role of COX-2 inhibition in breast cancer treatment and prevention; citation_author=B Arun; citation_author=P Goss; citation_volume=31; citation_publication_date=2004; citation_pages=22-29; citation_doi=10.1053/j.seminoncol.2004.03.042; citation_id=CR8;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression; citation_author=SH Chang; citation_author=CH Liu; citation_author=R Conway; citation_author=DK Han; citation_author=K Nithipatikom; citation_author=OC Trifan; citation_author=TF Lane; citation_author=T Hla; citation_volume=101; citation_publication_date=2004; citation_pages=591-596; citation_doi=10.1073/pnas.2535911100; citation_id=CR9;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Res; citation_title=Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer; citation_author=LR Howe; citation_author=K Subbaramaiah; citation_author=J Patel; citation_author=JL Masferrer; citation_author=A Deora; citation_author=C Hudis; citation_author=HT Thaler; citation_author=WJ Muller; citation_author=B Du; citation_author=AM Brown; citation_author=AJ Dannenberg; citation_volume=62; citation_publication_date=2002; citation_pages=5405-5407; citation_id=CR10;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Res; citation_title=Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor; citation_author=RE Harris; citation_author=GA Alshafie; citation_author=H Abou-Issa; citation_author=K Seibert; citation_volume=60; citation_publication_date=2000; citation_pages=2101-2103; citation_id=CR11;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Int J Dev Biol; citation_title=Role of cancer-associated fibroblasts in breast cancer development and prognosis; citation_author=A Aboussekhra; citation_volume=55; citation_publication_date=2011; citation_pages=841-849; citation_doi=10.1387/ijdb.113362aa; citation_id=CR12;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cell; citation_title=Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion; citation_author=A Orimo; citation_author=PB Gupta; citation_author=DC Sgroi; citation_author=F Arenzana-Seisdedos; citation_author=T Delaunay; citation_author=R Naeem; citation_author=VJ Carey; citation_author=AL Richardson; citation_author=RA Weinberg; citation_volume=121; citation_publication_date=2005; citation_pages=335-348; citation_doi=10.1016/j.cell.2005.02.034; citation_id=CR13;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Molecular characterization of the tumor microenvironment in breast cancer; citation_author=M Allinen; citation_author=R Beroukhim; citation_author=L Cai; citation_author=C Brennan; citation_author=J Lahti-Domenici; citation_author=H Huang; citation_author=D Porter; citation_author=M Hu; citation_author=L Chin; citation_author=A Richardson; citation_author=S Schnitt; citation_author=WR Sellers; citation_author=K Polyak; citation_volume=6; citation_publication_date=2004; citation_pages=17-32; citation_doi=10.1016/j.ccr.2004.06.010; citation_id=CR14;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast; citation_author=M Hu; citation_author=G Peluffo; citation_author=H Chen; citation_author=R Gelman; citation_author=S Schnitt; citation_author=K Polyak; citation_volume=106; citation_publication_date=2009; citation_pages=3372-3377; citation_doi=10.1073/pnas.0813306106; citation_id=CR15;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Reconstruction of functionally normal and malignant human breast tissues in mice; citation_author=C Kuperwasser; citation_author=T Chavarria; citation_author=M Wu; citation_author=G Magrane; citation_author=JW Gray; citation_author=L Carey; citation_author=A Richardson; citation_author=RA Weinberg; citation_volume=101; citation_publication_date=2004; citation_pages=4966-4971; citation_doi=10.1073/pnas.0401064101; citation_id=CR16;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan; citation_author=HH Cheng; citation_author=CC Kuo; citation_author=JL Yan; citation_author=HL Chen; citation_author=WC Lin; citation_author=KH Wang; citation_author=KK Tsai; citation_author=H Guv&#233;n; citation_author=E Flaberg; citation_author=L Szekely; citation_author=G Klein; citation_author=KK Wu; citation_volume=109; citation_publication_date=2012; citation_pages=13231-13236; citation_doi=10.1073/pnas.1209919109; citation_id=CR17;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nucleic Acid Res; citation_title=HMDB: a knowledge base for the human metabolome; citation_author=DS Wishart; citation_author=C Knox; citation_author=AC Guo; citation_author=R Eisner; citation_author=N Young; citation_author=B Gautam; citation_author=DD Hau; citation_author=N Psychogios; citation_author=E Dong; citation_author=S Bouatra; citation_author=R Mandal; citation_author=I Sinelnikov; citation_author=J Xia; citation_author=L Jia; citation_author=JA Cruz; citation_author=E Lim; citation_author=CA Sobsey; citation_author=S Shrivastava; citation_author=P Huang; citation_author=P Liu; citation_author=L Fang; citation_author=J Peng; citation_author=R Fradette; citation_author=D Cheng; citation_author=D Tzur; citation_author=M Clements; citation_author=A Lewis; citation_author=A De Souza; citation_author=A Zuniga; citation_author=M Dawe; citation_volume=37; citation_publication_date=2009; citation_pages=D603-610; citation_doi=10.1093/nar/gkn810; citation_id=CR18;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cell; citation_title=The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis; citation_author=CH Chan; citation_author=CF Li; citation_author=WL Yang; citation_author=Y Gao; citation_author=SW Lee; citation_author=Z Feng; citation_author=HY Huang; citation_author=KK Tsai; citation_author=LG Flores; citation_author=Y Shao; citation_author=JD Hazle; citation_author=D Yu; citation_author=W Wei; citation_author=D Sarbassov; citation_author=MC Hung; citation_author=KI Nakayama; citation_author=HK Lin; citation_volume=149; citation_publication_date=2012; citation_pages=1098-1111; citation_doi=10.1016/j.cell.2012.02.065; citation_id=CR19;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Mass Spectrom; citation_title=MassBank: a public repository for sharing mass spectral data for life sciences; citation_author=H Horai; citation_author=M Arita; citation_author=S Kanaya; citation_author=Y Nihei; citation_author=T Ikeda; citation_author=K Suwa; citation_author=Y Ojima; citation_author=K Tanaka; citation_author=S Tanaka; citation_author=K Aoshima; citation_author=Y Oda; citation_author=Y Kakazu; citation_author=M Kusano; citation_author=T Tohge; citation_author=F Matsuda; citation_author=Y Sawada; citation_author=MY Hirai; citation_author=H Nakanishi; citation_author=K Ikeda; citation_author=N Akimoto; citation_author=T Maoka; citation_author=H Takahashi; citation_author=T Ara; citation_author=N Sakurai; citation_author=H Suzuki; citation_author=D Shibata; citation_author=S Neumann; citation_author=T Iida; citation_author=K Tanaka; citation_author=K Funatsu; citation_volume=45; citation_publication_date=2010; citation_pages=703-714; citation_doi=10.1002/jms.1777; citation_id=CR20;'/>
    
    <meta name="citation_reference" content='citation_journal_title=PLoS One; citation_title=Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene; citation_author=M Soichot; citation_author=B Hennart; citation_author=A Al Saabi; citation_author=A Leloire; citation_author=P Froguel; citation_author=C Levy-Marchal; citation_author=O Poulain-Godefroy; citation_author=D Allorge; citation_volume=6; citation_publication_date=2011; citation_pages=e25470; citation_doi=10.1371/journal.pone.0025470; citation_id=CR21;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Interferon Cytokine Res; citation_title=GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression; citation_author=T Decker; citation_author=P Kovarik; citation_author=A Meinke; citation_volume=17; citation_publication_date=1997; citation_pages=121-134; citation_doi=10.1089/jir.1997.17.121; citation_id=CR22;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Interferon Cytokine Res; citation_title=Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma; citation_author=MX Du; citation_author=WD Sotero-Esteva; citation_author=MW Taylor; citation_volume=20; citation_publication_date=2000; citation_pages=133-142; citation_doi=10.1089/107999000312531; citation_id=CR23;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Immunol; citation_title=Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO; citation_author=TL Sumpter; citation_author=A Dangi; citation_author=BM Matta; citation_author=C Huang; citation_author=DB Stolz; citation_author=Y Vodovotz; citation_author=AW Thomson; citation_author=CR Gandhi; citation_volume=189; citation_publication_date=2012; citation_pages=3848-3858; citation_doi=10.4049/jimmunol.1200819; citation_id=CR24;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor; citation_author=CA Opitz; citation_author=UM Litzenburger; citation_author=F Sahm; citation_author=M Ott; citation_author=I Tritschler; citation_author=S Trump; citation_author=T Schumacher; citation_author=L Jestaedt; citation_author=D Schrenk; citation_author=M Weller; citation_author=M Jugold; citation_author=GJ Guillemin; citation_author=CL Miller; citation_author=C Lutz; citation_author=B Radlwimmer; citation_author=I Lehmann; citation_author=A von Deimling; citation_author=W Wick; citation_author=M Platten; citation_volume=478; citation_publication_date=2011; citation_pages=197-203; citation_doi=10.1038/nature10491; citation_id=CR25;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Dioxin receptor is a ligand-dependent E3 ubiquitin ligase; citation_author=F Ohtake; citation_author=A Baba; citation_author=I Takada; citation_author=M Okada; citation_author=K Iwasaki; citation_author=H Miki; citation_author=S Takahashi; citation_author=A Kouzmenko; citation_author=K Nohara; citation_author=T Chiba; citation_author=Y Fujii-Kuriyama; citation_author=S Kato; citation_volume=446; citation_publication_date=2007; citation_pages=562-566; citation_doi=10.1038/nature05683; citation_id=CR26;'/>
    
    <meta name="citation_reference" content='citation_journal_title=BMC Cancer; citation_title=Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer; citation_author=AS Mansfield; citation_author=PS Heikkila; citation_author=AT Vaara; citation_author=KA von Smitten; citation_author=JM Vakkila; citation_author=MH Leidenius; citation_volume=9; citation_publication_date=2009; citation_pages=231; citation_doi=10.1186/1471-2407-9-231; citation_id=CR27;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Exp Med; citation_title=Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase; citation_author=G Frumento; citation_author=R Rotondo; citation_author=M Tonetti; citation_author=G Damonte; citation_author=U Benatti; citation_author=GB Ferrara; citation_volume=196; citation_publication_date=2002; citation_pages=459-468; citation_doi=10.1084/jem.20020121; citation_id=CR28;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Med; citation_title=Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy; citation_author=AJ Muller; citation_author=JB DuHadaway; citation_author=PS Donover; citation_author=E Sutanto-Ward; citation_author=GC Prendergast; citation_volume=11; citation_publication_date=2005; citation_pages=312-319; citation_doi=10.1038/nm1196; citation_id=CR29;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients; citation_author=H Yasui; citation_author=K Takai; citation_author=R Yoshida; citation_author=O Hayaishi; citation_volume=83; citation_publication_date=1986; citation_pages=6622-6626; citation_doi=10.1073/pnas.83.17.6622; citation_id=CR30;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Biol Chem; citation_title=Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells; citation_author=MR Pan; citation_author=MF Hou; citation_author=HC Chang; citation_author=WC Hung; citation_volume=283; citation_publication_date=2008; citation_pages=11155-11163; citation_doi=10.1074/jbc.M710038200; citation_id=CR31;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Exp Med; citation_title=Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations; citation_author=S Gross; citation_author=RA Cairns; citation_author=MD Minden; citation_author=EM Driggers; citation_author=MA Bittinger; citation_author=HG Jang; citation_author=M Sasaki; citation_author=S Jin; citation_author=DP Schenkein; citation_author=SM Su; citation_author=L Dang; citation_author=VR Fantin; citation_author=TW Mak; citation_volume=207; citation_publication_date=2010; citation_pages=339-344; citation_doi=10.1084/jem.20092506; citation_id=CR32;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate; citation_author=PS Ward; citation_author=J Patel; citation_author=DR Wise; citation_author=O Abdel-Wahab; citation_author=BD Bennett; citation_author=HA Coller; citation_author=JR Cross; citation_author=VR Fantin; citation_author=CV Hedvat; citation_author=AE Perl; citation_author=JD Rabinowitz; citation_author=M Carroll; citation_author=SM Su; citation_author=KA Sharp; citation_author=RL Levine; citation_author=CB Thompson; citation_volume=17; citation_publication_date=2010; citation_pages=225-234; citation_doi=10.1016/j.ccr.2010.01.020; citation_id=CR33;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation; citation_author=ME Figueroa; citation_author=O Abdel-Wahab; citation_author=C Lu; citation_author=PS Ward; citation_author=J Patel; citation_author=A Shih; citation_author=Y Li; citation_author=N Bhagwat; citation_author=A Vasanthakumar; citation_author=HF Fernandez; citation_author=MS Tallman; citation_author=Z Sun; citation_author=K Wolniak; citation_author=JK Peeters; citation_author=W Liu; citation_author=SE Choe; citation_author=VR Fantin; citation_author=E Paietta; citation_author=B Lowenberg; citation_author=JD Licht; citation_author=LA Godley; citation_author=R Delwel; citation_author=PJ Valk; citation_author=CB Thompson; citation_author=RL Levine; citation_author=A Melnick; citation_volume=18; citation_publication_date=2010; citation_pages=553-567; citation_doi=10.1016/j.ccr.2010.11.015; citation_id=CR34;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases; citation_author=W Xu; citation_author=H Yang; citation_author=Y Liu; citation_author=Y Yang; citation_author=P Wang; citation_author=SH Kim; citation_author=S Ito; citation_author=C Yang; citation_author=P Wang; citation_author=MT Xiao; citation_author=LX Liu; citation_author=WQ Jiang; citation_author=J Liu; citation_author=JY Zhang; citation_author=B Wang; citation_author=S Frye; citation_author=Y Zhang; citation_author=YH Xu; citation_author=QY Lei; citation_author=KL Guan; citation_author=SM Zhao; citation_author=Y Xiong; citation_volume=19; citation_publication_date=2011; citation_pages=17-30; citation_doi=10.1016/j.ccr.2010.12.014; citation_id=CR35;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Res; citation_title=Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion; citation_author=M Platten; citation_author=W Wick; citation_author=BJ Van den Eynde; citation_volume=72; citation_publication_date=2012; citation_pages=5435-5440; citation_doi=10.1158/0008-5472.CAN-12-0569; citation_id=CR36;'/>
    
    <meta name="citation_reference" content='citation_journal_title=PLoS Biol; citation_title=Determination of stromal signatures in breast carcinoma; citation_author=RB West; citation_author=DS Nuyten; citation_author=S Subramanian; citation_author=TO Nielsen; citation_author=CL Corless; citation_author=BP Rubin; citation_author=K Montgomery; citation_author=S Zhu; citation_author=R Patel; citation_author=T Hernandez-Boussard; citation_author=JR Goldblum; citation_author=PO Brown; citation_author=M van de Vijver; citation_author=M van de Rijn; citation_volume=3; citation_publication_date=2005; citation_pages=e187; citation_doi=10.1371/journal.pbio.0030187; citation_id=CR37;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Clin Cancer Res; citation_title=Stromal responses among common carcinomas correlated with clinicopathologic features; citation_author=JL Chen; citation_author=I Espinosa; citation_author=AY Lin; citation_author=OY Liao; citation_author=M van de Rijn; citation_author=RB West; citation_volume=19; citation_publication_date=2013; citation_pages=5127-5135; citation_doi=10.1158/1078-0432.CCR-12-3127; citation_id=CR38;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Biol Ther; citation_title=Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy; citation_author=I Mercier; citation_author=MC Casimiro; citation_author=C Wang; citation_author=AL Rosenberg; citation_author=J Quong; citation_author=A Minkeu; citation_author=KG Allen; citation_author=C Danilo; citation_author=F Sotgia; citation_author=G Bonuccelli; citation_author=JF Jasmin; citation_author=H Xu; citation_author=E Bosco; citation_author=B Aronow; citation_author=A Witkiewicz; citation_author=RG Pestell; citation_author=ES Knudsen; citation_author=MP Lisanti; citation_volume=7; citation_publication_date=2008; citation_pages=1212-1225; citation_doi=10.4161/cbt.7.8.6220; citation_id=CR39;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner; citation_author=N Erez; citation_author=M Truitt; citation_author=P Olson; citation_author=ST Arron; citation_author=D Hanahan; citation_volume=17; citation_publication_date=2010; citation_pages=135-147; citation_doi=10.1016/j.ccr.2009.12.041; citation_id=CR40;'/>
    
    <meta name="prism.doi" content='10.1186/s13058-014-0410-1'/>
    
    <meta name="dc.identifier" content='10.1186/s13058-014-0410-1'/>
    
    <meta name="citation_doi" content='10.1186/s13058-014-0410-1'/>
    
    <meta name="citation_abstract" content='&lt;h2&gt;Abstract&lt;/h2&gt; &lt;h3&gt;Introduction&lt;/h3&gt; Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear.  &lt;h3&gt;Methods&lt;/h3&gt; Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E&lt;sub&gt;2&lt;/sub&gt; (PGE&lt;sub&gt;2&lt;/sub&gt;) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on tumor growth.  &lt;h3&gt;Results&lt;/h3&gt; Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. PGE&lt;sub&gt;2&lt;/sub&gt; released by cancer cells upregulates IDO expression in fibroblasts through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely, fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors inhibit tumor growth &lt;i&gt;in vivo&lt;/i&gt;.  &lt;h3&gt;Conclusion&lt;/h3&gt; Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival.'/>
    
    <meta name="DOI" content='10.1186/s13058-014-0410-1'/>
    

        
    <script type="text/javascript">
        dataLayer = [{"content":{"article":{"doi":"10.1186/s13058-014-0410-1","articleType":"Research article","peerReviewType":"Closed"},"contentInfo":{"imprint":"BioMed Central","title":"Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression","publishedAt":1406246400000,"publishedAtDate":"2014-07-25","authors":["Jing-Yi Chen","Chien-Feng Li","Cheng-Chin Kuo","Kelvin K Tsai","Ming-Feng Hou","Wen-Chun Hung"],"collections":[]},"attributes":{"deliveryPlatform":"oscar","template":null,"cms":null,"copyright":{"creativeCommonsType":null}},"journal":{"volume":"16","issue":"4","title":"Breast Cancer Research","category":"AJ","id":13058},"category":{"pmc":{"primarySubject":"Biomedicine"}}}}]

    </script>

        

        <meta charset="UTF-8"/>
        <meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <meta name="viewport" content="width=device-width, initial-scale=1"/>
        <!-- For IE 9 and below -->
<!--[if IE]><link rel="shortcut icon" href=/static/images/favicons/biomedcentral/favicon-dc10a51d5f.ico><![endif]-->
<!-- Touch Icons - iOS and Android 2.1+ -->
<link rel="apple-touch-icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
<!-- Firefox, Chrome, Safari, IE 11+ and Opera -->
<link rel="icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
        <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'js')})(document.documentElement)</script>
        <script>(function(d) {if (sessionStorage.getItem('webfonts') == 'true'){d.className += ' webfonts-loaded';}})(document.documentElement);</script>
        <link rel="stylesheet" media="screen" href=/static/styles/basic/basic-8a9ed7dce9.css>
<link rel="stylesheet" media="print" href=/static/styles/biomedcentral/biomedcentral-print-9d9c0bc8d5.css>

<link rel="stylesheet" class="js-ctm" href=/static/styles/biomedcentral/biomedcentral-1a58e9106c.css
      media="only screen and (-webkit-min-device-pixel-ratio:0) and (min-color-index:0), (-ms-high-contrast: none), only all and (min--moz-device-pixel-ratio:0) and (min-resolution: 3e1dpcm)">
        
    <script type="text/javascript">
        config = {
            env: 'live',
            site: 'breast-cancer-research.biomedcentral.com',
            siteWithPath: 'breast-cancer-research.biomedcentral.com' + window.location.pathname,
            twitterHashtag: '',
            cmsPrefix: 'http://studio-cms.springer.com/studio/',
            
            doi: '10.1186/s13058-014-0410-1',
            figshareScriptUrl: 'https://widgets.figshare.com/static/figshare.js',
            publisherBrand: 'BioMed Central'
        };
    </script>

        
    
    <script>
        window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;

        (function() {
            var sampleRate = 20;

            ga('create', "UA-62064032-16", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate
            });

            ga("set", "anonymizeIp", true);
            ga('send', 'pageview');

        
            ga('create', "UA-54492316-9", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate,
                name: 'global'
            });
            ga("global.set", "anonymizeIp", true);
            ga('global.send', 'pageview');
            ga('set', 'transport', 'beacon');
        
        }())
    </script>
    <script async src='https://www.google-analytics.com/analytics.js'></script>
    

        
    
    <link rel="canonical" href="//breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0410-1"/>
    


        

        
        
    <meta property="og:url" content="https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0410-1"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="Breast Cancer Research"/>
    <meta property="og:title" content="Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression"/>
    <meta property="og:description" content="Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear. Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E2 (PGE2) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on tumor growth. Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. PGE2 released by cancer cells upregulates IDO expression in fibroblasts through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely, fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors inhibit tumor growth in vivo. Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival."/>
    <meta property="og:image" content="https://images.springer.com/sgw/journals/medium/13058.jpg"/>

        
    </head>

    <body class="fulltext" >
    
    
        
    

    
    <div class="container" style="height: 0"><div id="wt_refpoint"></div></div>
    <p class="skip-to-main">
    <a class="skip-to-main__link" href="#main">Skip to main content</a>
</p>

    <div id="top">
        
<div id="RealMediaLeaderboard" class="adsbox RealMediaAd Ad Ad--leaderboard" data-position="Top">
    <div class="Ad_content">
        <p class="Ad_label">Advertisement</p>
        
    </div>
</div>


        



         
    <div id="membership-message-loader-desktop" class="placeholder" data-placeholder="/placeholder/v1/membership/message"></div>
    <header class="header" role="banner">
        <div class="header__inner">
            <a id="header-logo" href="//www.biomedcentral.com/" class="logo header__logo" title="BioMed Central">
                <img srcset="/static/images/biomed-central-logo-976eb64772.svg" src="/static/images/biomed-central-logo-5300b47908.png" class="logo__img" alt="Biomed Central" />
            </a>
            <div class="header__right">
                <div class="toggles js-fade-toggle">
                    <p id="loginLink" class="sign-in toggles__item" data-replace="true" data-placeholder="/placeholder/v1/username">
    <a class="sign-in__link" href="//www.biomedcentral.com/login" data-track-event="click" data-event-category="Account" data-event-action="Click Login Link">
        <span class="sign-in__no-js-account-hide">Login
            <span class="sign-in__js-account-hide"> to </span>
        </span>
        <span class="sign-in__js-account-hide sign-in__no-js-capitalise">your account</span>
    </a>
</p>
                    
                    <a href="#globalSearch" class="toggles__item toggles__item--search" data-toggle="search"><span class="sr-only">Search</span></a>
                </div>
                <form role="search" id="globalSearch" class="search search--expandable header__search" method="GET" action="//www.biomedcentral.com/search" data-track-event="submit"
      data-event-category="Search and Results" data-event-action="Submit search" data-event-label="">
    <div class="search__content">
        <label for="publisherSearch" class="sr-only">Search BioMed Central articles</label>
        <input id="publisherSearch" class="search__input" autocomplete="off" role="textbox" name="query" type="text" value="" title="Search BioMed Central" placeholder="Search BioMed Central articles"/>
        <button id="search" class="search__button" type="submit">
            <span class="sr-only">Search</span>
        </button>
        <input type="hidden" name="searchType" value="publisherSearch"/>
    </div>
</form>

            </div>
            
        </div>
    </header>

        <main role="main">
            
            <header class="journal-header" role="banner">
                <div class="journal-header__inner">
                    <h2 class="journal-header__title journal-header__title--medium" id="journalTitle">
                        
                        <a class="journal-header__title-text" href="/">
                            Breast Cancer Research
                        </a>
                    </h2>
                    
                </div>
                <div class="navbar">
                    <div class="navbar__inner">
                        
<p class="impact-factor">
    <span class="impact-factor__label">Impact Factor</span> <span class="impact-factor__value">6.345</span>
</p>


                        
                        <nav class="navbar__nav">
                            <h3 class="navbar__menu-toggle" data-toggle="collapse" data-target="journal-menu">
                                <span class="sr-only">Main </span>menu
                            </h3>
                            <ul id="journal-menu" class="navbar__menu" id="siteNavigation" role="menu">
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/'>Home</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/about'>About</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link is-active" href='/articles'>Articles</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/submission-guidelines'>Submission Guidelines</a>
                                    </li>
                                
                            </ul>
                        </nav>
                        
                    </div>
                </div>
                <div class="journal-identity journal-identity--globules-purple">
                    
                </div>
            </header>
            
        
            <div class="container">
                
                <div id="main" class="layout">
                
                    <div class="layout__main--wide" id="main-content">
                        <div class="block" id="Test-ImgSrc">
                            
                            
    <div class="FulltextWrapper">
        <div class="Categories">
            <div class="ArticleCategory">Research article</div>
            <div class="OpenAccessLabel">Open Access</div>
            
        </div>
        
    </div>

                            <div class="FulltextWrapper"><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="MainTitleSection"><h1 xmlns="http://www.w3.org/1999/xhtml" class="ArticleTitle" lang="en">Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression</h1></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="AuthorNames" data-author-affiliations="true"><ul class="u-listReset"><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Jing-Yi&nbsp;Chen</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Chien-Feng&nbsp;Li</span><sup><a href="#Aff2" class="AffiliationID">2</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Cheng-Chin&nbsp;Kuo</span><sup><a href="#Aff3" class="AffiliationID">3</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Kelvin&nbsp;K&nbsp;Tsai</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Ming-Feng&nbsp;Hou</span><sup><a href="#Aff4" class="AffiliationID">4</a>, <a href="#Aff5" class="AffiliationID">5</a>, <a href="#Aff6" class="AffiliationID">6</a></sup> and </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Wen-Chun&nbsp;Hung</span><sup><a href="#Aff1" class="AffiliationID">1</a>, <a href="#Aff6" class="AffiliationID">6</a>, <a href="#Aff7" class="AffiliationID">7</a></sup><a href="mailto:hung1228@nhri.org.tw" class="EmailAuthor" title="Email author"><span class="ContactIcon" aria-hidden="true"></span><span class="u-srOnly">Email author</span></a></li></ul></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="ArticleContextInformation"><div class="ContextInformation"><div class="ContextInformationJournalTitles"><span class="ArticleCitation"><span xmlns="http://www.w3.org/1999/xhtml" class="JournalTitle">Breast Cancer Research</span><span class="ArticleCitation_Year">2014</span><span class="ArticleCitation_Volume"><strong>16</strong>:410</span></span></div><p class="ArticleDOI"><a target="_blank" href="https://doi.org/10.1186/s13058-014-0410-1">https://doi.org/10.1186/s13058-014-0410-1</a></p><p class="Copyright">Â© &nbsp;Chen et al.; licensee BioMed Central; licensee BioMed Central Ltd.&nbsp;2014</p></div></div><div class="ArticleHistory"><p class="History HistoryReceived"><strong>Received: </strong>14&nbsp;January&nbsp;2014</p><p class="History HistoryAccepted"><strong>Accepted: </strong>10&nbsp;July&nbsp;2014</p><p class="History HistoryOnlineDate"><strong>Published: </strong>25&nbsp;July&nbsp;2014</p></div></div>
                            
                            
                            
    

                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Abstract" id="Abs1" lang="en"><h2 class="Heading js-ToggleCollapseSection">Abstract</h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec1">
                <h3 xmlns="" class="Heading">Introduction</h3>
                <p class="Para">Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec2">
                <h3 xmlns="" class="Heading">Methods</h3>
                <p class="Para">Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on tumor growth.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec3">
                <h3 xmlns="" class="Heading">Results</h3>
                <p class="Para">Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. PGE<sub>2</sub> released by cancer cells upregulates IDO expression in fibroblasts through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely, fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors inhibit tumor growth <em xmlns="" class="EmphasisTypeItalic">in vivo</em>.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec4">
                <h3 xmlns="" class="Heading">Conclusion</h3>
                <p class="Para">Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival.</p>
              </div></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec1" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Background</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Chronic inflammation is strongly associated with the development of cancer [<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>]-â[<span class="CitationRef"><a href="#CR3" data-toggle="citation" data-target="CR3">3</a></span>]. One of the crucial mediators of inflammatory reaction is cyclooxygenase (COX). The COX family of enzymes comprises two members (COX-1 and COX-2) and is the main controller of eicosanoid biosynthesis. Studies of human breast tumor tissues demonstrate that upregulation of COX-2 has been detected in approximately 40% of human breast tumor tissues, as well as preinvasive ductal carcinoma <em xmlns="" class="EmphasisTypeItalic">in situ</em> lesions [<span class="CitationRef"><a href="#CR4" data-toggle="citation" data-target="CR4">4</a></span>]. Elevated expression of COX-2 is associated with large tumor size, advanced histologic grade, axillary node metastasis, and unfavorable disease-free survival [<span class="CitationRef"><a href="#CR4" data-toggle="citation" data-target="CR4">4</a></span>],[<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>]. In addition, COX-2 expression also links with increased tumor angiogenesis [<span class="CitationRef"><a href="#CR6" data-toggle="citation" data-target="CR6">6</a></span>]. Epidemiologic investigations suggest that use of nonsteroidal antiinflammatory drugs or selective COX-2 inhibitors reduces breast cancer risk [<span class="CitationRef"><a href="#CR7" data-toggle="citation" data-target="CR7">7</a></span>],[<span class="CitationRef"><a href="#CR8" data-toggle="citation" data-target="CR8">8</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Results of animal study also support an oncogenic role of COX-2. Transgenic COX-2 overexpression induces mammary tumor formation in mice [<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>]. This tumorigenic transformation is highly dependent on PGE<sub>2</sub> production and angiogenic switch. In addition, <em xmlns="" class="EmphasisTypeItalic">HER-2/Neu</em> oncogene-induced mammary tumorigenesis and angiogenesis are dramatically attenuated in COX-2 knockout mice, suggesting a key role of COX-2 in breast cancer [<span class="CitationRef"><a href="#CR10" data-toggle="citation" data-target="CR10">10</a></span>]. Recent studies also show that COX-2 inhibitors exhibit antitumor and antiangiogenic activities <em xmlns="" class="EmphasisTypeItalic">in vivo</em> and exhibit chemopreventive effects against mammary carcinogenesis induced by 7,12-dimethyl-benz(a)anthracene in rats [<span class="CitationRef"><a href="#CR11" data-toggle="citation" data-target="CR11">11</a></span>]. All of the results suggest that COX-2 is involved in multiple steps of breast carcinogenesis and is a potential target for cancer prevention and therapy.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Interplay between breast cancer cells and cancer-associated fibroblasts (CAFs), the most abundant and active stromal cells, is crucial for tumor growth, progression, angiogenesis, and therapeutic resistance [<span class="CitationRef"><a href="#CR12" data-toggle="citation" data-target="CR12">12</a></span>]. Cancer cells release a number of factors to enhance the production of cytokines, chemokines, and matrix metalloproteinases (MMPs) from CAFs, which in turn facilitate cancer cell proliferation, migration, and invasion. Previous study demonstrated that stromal fibroblasts present in invasive breast carcinomas can secrete large amounts of stromal cell-derived factor 1 (SDF-1) to enhance tumor growth and angiogenesis [<span class="CitationRef"><a href="#CR13" data-toggle="citation" data-target="CR13">13</a></span>]. Co-injection of breast cancer cells and fibroblasts also promotes the progression of ductal carcinoma <em xmlns="" class="EmphasisTypeItalic">in situ</em> to invasive breast carcinoma by stimulating chemokine (C-X-C motif) ligand 14 (CXCL14) and chemokine (C-X-C motif) ligand 12 (CXCL12) production [<span class="CitationRef"><a href="#CR14" data-toggle="citation" data-target="CR14">14</a></span>]. However, most studies addressing the crosstalk between cancer and stromal cells focus on protein factors like cytokines and chemokines. Whether other small molecules such as lipids or metabolites participate in cancer-stromal cell interaction is largely unknown.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The tumor-promoting role of CAFs via upregulation of COX-2 in ductal carcinoma <em xmlns="" class="EmphasisTypeItalic">in situ</em> of the breast was first demonstrated by Hu <em xmlns="" class="EmphasisTypeItalic">et al</em>. [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>]. The authors showed that co-culture with fibroblasts increases COX-2 expression in breast cancer cells and subsequently induces MMP-9 and MMP-14 in these cells to promote invasion. They also elucidated the underlying mechanism by demonstrating that inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) and COX-2 activity reduces the invasion-promoting effect of fibroblasts. These data suggest that fibroblasts secrete some factors to activate NF-ÎºB-mediated transcription of COX-2 in breast cancer cells to enhance tumor progression.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">However, several issues remain elusive. First, does PGE<sub>2</sub> generated by COX-2-expressing cancer cells also affect gene expression or behavior of stromal fibroblasts? Second, do CAFs secrete small molecules (other than proteins or peptides) to regulate cancer cell invasion? Finally, can the importance of cancer-stroma interaction in cancer progression be validated in clinical samples?</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In this study, we address these questions and try to clarify the underlying mechanism.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec2" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Methods</h2><div class="js-CollapseSection"><section id="Sec3" class="Section2 RenderAsSection2">
                <h3 class="Heading">Cell culture</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Human breast cancer cell lines MCF-7 and MDA-MB-231 were purchased from the Bioresource Collection and Research Center (BCRC) and ATCC. Immortalized human breast fibroblasts, RMF-EG [<span class="CitationRef"><a href="#CR16" data-toggle="citation" data-target="CR16">16</a></span>], were kindly provided by Dr. Charlotte Kuperwasser (Tufts University, Boston, MA, USA). These cells were cultured in DMEM/F12 containing 10% fetal bovine serum (FBS). Other experimental materials and procedures are provided in Additional file <span class="InternalRef"><a href="#MOESM1">1</a></span>.</p>
              </section><section id="Sec4" class="Section2 RenderAsSection2">
                <h3 class="Heading">Establishment of inducible COX-2-expression MCF-7 cell line</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">To establish an inducible COX-2-expression cell line, MCF-7 cells (1âÃâ10<sup>6</sup>) were resuspended in buffer R containing 2&nbsp;Î¼g pCMV-Tet3G plasmid. Transfection was performed by using Neon microporation transfection system at room temperature with 1,250&nbsp;V, 20 milliseconds, and two pulses. After 48&nbsp;hours, the cells were selected with 1&nbsp;mg/ml&nbsp;G418 for 2&nbsp;weeks.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">For the delivery of the second plasmid, pCMV-Tet3G stably transfected cells (1âÃâ10<sup>6</sup>) were resuspended in buffer R containing 2&nbsp;Î¼g of pTRE-mCherry-COX-2 plasmid. Transfection was performed by using Neon microporation transfection system at room temperature with 1,250&nbsp;V, 20 milliseconds, and two pulses. After 48&nbsp;hours, the cells were subjected to selection with 100&nbsp;Î¼g/ml hygromycin B. The stable cell line harbors both pCMV-Tet3G and pTRE-mCherry-COX-2 plasmid was used for induction experiment. The cells were maintained at 37Â°C in a 5% CO<sub>2</sub>-humidified atmosphere and were incubated with doxycycline to induce COX-2 expression before co-culture assay.</p>
              </section><section id="Sec5" class="Section2 RenderAsSection2">
                <h3 class="Heading">Co-culture assay</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In the co-culture system, 1âÃâ10<sup>5</sup> RMF-EG cells were grown in the bottom of a six-well plate in DMEM/F12 with 10% FBS, and 1âÃâ10<sup>6</sup> breast cancer cells were seeded on the 0.4-Î¼m polyester membrane of a transwell insert in the same medium. MCF-7 cells were treated with or without doxycycline (1&nbsp;Î¼g/ml) for 72&nbsp;hours. The conditioned medium, breast cancer cells, and RMF-EG cells were harvested for metabolomics and Western blotting analysis.</p>
              </section><section id="Sec6" class="Section2 RenderAsSection2">
                <h3 class="Heading">Metabolite profiling</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The proteins in the conditioned medium were removed by using 3-kDa ultracentrifugation filter devices. The metabolites in the filtered medium were extracted by using iced 50% methanol and were subsequently dried by a speedvac. Metabolite profiles were analyzed with the Metabolomics Core of National Health Research Institutes by using a high-resolution ultraperformance liquid chromatography (UPLC) coupled online to a triple-quadrupole time-of-flight mass spectrometry system, as described previously [<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>]. Metabolite identity was predicted with Human Metabolome Database [<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>].</p>
              </section><section id="Sec7" class="Section2 RenderAsSection2">
                <h3 class="Heading">RNA extraction and quantitative reverse transcription-PCR analysis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Total RNA was isolated from cells by using an RNA extraction kit (Qiagen, Valencia, CA, USA) and 1&nbsp;Î¼g of RNA was reverse-transcribed to cDNA. Target mRNAs were quantified by using real-time PCR reactions with SYBR green fluorescein, and actin served as an internal control. cDNA synthesis was performed at 95Â°C for 3&nbsp;minutes, and the conditions for PCR were 28&nbsp;cycles of denaturation (95Â°C/1&nbsp;minute), annealing (60Â°C/1&nbsp;minute) extension (72Â°C/1&nbsp;minute), and 1&nbsp;cycle of final extension (72Â°C/10&nbsp;minutes). The primers used are tryptophan 2,3-dioxygenase (TDO)-forward: 5â²-GGGAACTACCTGCATTTGGA-3â²; TDO-reverse: 5â²-GTGCATCCGAGAAACAACCT-3â²; IDO-forward: 5â²-GCGCTGTTGGAAATAGCTTC-3â²; IDO-reverse: 5â²-CAGGACGTCAAAGCACTGAA-3â²; E-cadherin-forward: 5â²-CCTGGGACTCCACCTACAGA-3â²; E-cadherin-reverse: 5â²-GGATGAACACAGCGTGAGAGA-3â²; actin-forward: 5â²-TGTTACCAACTGGGACGACA-3â²; actin-reverse: 5â²-GGGGTGTTGAAGGTCTCAAA-3â².</p>
              </section><section id="Sec8" class="Section2 RenderAsSection2">
                <h3 class="Heading">Immunoprecipitation and Western blot analysis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">MCF-7or COX-2-overexpressing MCF-7 cells were treated with or without 100&nbsp;Î¼<em xmlns="" class="EmphasisTypeItalic">M</em> kynurenine for 24&nbsp;hours; the cells were harvested with an RIPA buffer (50&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> TrisâHCl, pH&nbsp;7.4, 150&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 2&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> EDTA, and 50&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> NaF), and cellular lysates were incubated with anti-AhR antibody overnight at 4Â°C with rotation. Immunocomplexes were pulled down by Protein-G agarose bead, washed with RIPA buffer 3 times, and eluted with a sample buffer in boiled water for 10&nbsp;minutes. The eluted samples were subjected to SDS-PAGE separation, and proteins were transferred to nitrocellulose membranes. Finally, the blots were probed with anti-E-cadherin or anti-Skp2 antibody and developed with enhanced chemiluminescence reagent.</p>
              </section><section id="Sec9" class="Section2 RenderAsSection2">
                <h3 class="Heading">Migration assay</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Migration assays were conducted in transwells with 8-Î¼m-pore filter inserts. Then 1âÃâ10<sup>4</sup> MCF-7 or COX-2-overexpressing MCF-7 cells were seeded in the upper chamber. The lower chambers were filled with DMEM medium containing 1% FBS and 100&nbsp;Î¼<em xmlns="" class="EmphasisTypeItalic">M</em> kynurenine. After 24&nbsp;hours, the cells on the upper surface were removed by wiping with a cotton swab, and the cells that migrated to the lower surface were fixed. The cells were stained with 4â²,6-diamidino-2-phenylindole (DAPI), and the cell number in 15 randomly selected fields was counted under a microscope (100Ã). Experiments were performed independently at least 3 times.</p>
              </section><section id="Sec10" class="Section2 RenderAsSection2">
                <h3 class="Heading">Protein ubiquitination assay</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">MCF-7 cells treated with or without kynurenine were incubated with the proteasome inhibitor MG132 or the lysosome inhibitor chloroquine. The cells were harvested with a lysis buffer (20&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> TrisâHCl at pH&nbsp;7.5, 150&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> sodium chloride, 1&nbsp;m<em xmlns="" class="EmphasisTypeItalic">M</em> calcium chloride, and 1% Triton X-100 and protease inhibitors), and cellular lysates were incubated with an E-cadherin antibody overnight at 4Â°C with rotation. Protein-G beads were added to the samples and incubated for another 1&nbsp;hour at 4Â°C. Immunocomplexes were eluted and were subjected to SDS-PAGE separation, and proteins were transferred to nitrocellulose membranes. Finally, the blots were probed by using an anti-ubiquitin antibody to detect the ubiquitination status of E-cadherin.</p>
              </section><section id="Sec11" class="Section2 RenderAsSection2">
                <h3 class="Heading">Immunofluorescent staining and confocal microscopy</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">MCF-7 cells were treated with or without 100&nbsp;Î¼<em xmlns="" class="EmphasisTypeItalic">M</em> kynurenine for 6&nbsp;hours and fixed with 3.7% formaldehyde for 15&nbsp;minutes at room temperature. Cells were washed twice with PBS and permeabilized by 0.1% Triton X-100 solution for 10&nbsp;minutes. After permeabilization, cells were incubated with 0.05% BSA solution to block nonspecific binding. Anti-AhR mouse monoclonal antibody (1:80) or anti-E-cadherin goat polyclonal antibody (1:250) was added and incubated at room temperature for 1&nbsp;hour. After extensive washing, Alexas Fluro 594 anti-mouse IgG or Alexas Fluro 488 anti-goat IgG was added and incubated for another 1&nbsp;hour. Cell nuclei were stained with DAPI solution. Finally, coverslips were washed twice with PBS and subsequently placed in mounting solution. The fluorescent image was observed under a confocal microscope.</p>
              </section><section id="Sec12" class="Section2 RenderAsSection2">
                <h3 class="Heading"><em class="EmphasisTypeItalic">In vivo</em>orthotopic animal study</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">MCF-7 or MCF-7-COX2 (8âÃâ10<sup>6</sup>) cells were mixed with RMF-EG (6âÃâ10<sup>6</sup>) cells in Hanks balanced salt solution and Matrigel (BD Transduction Laboratories, San Jose, CA, USA). Cells were inoculated into the fourth mammary fat pads of 6-week-old female BALB/cAnN.Cg-Foxn1nu/CrlNarl mice. Before the inoculation of the cancer cell/fibroblast mixture, all mice were primed with 6&nbsp;mg/kg of 17Î²-estradiol twice a week for 3&nbsp;weeks.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">After inoculation, 17Î²-estradiol was continuously given to mice throughout the experiments. Measurement of tumor growth was begun at 4&nbsp;weeks after injection, and tumor volume was calculated by using the equation: tumor volumeâ=â(lengthâÃâwidth<sup>2</sup>)/2. After 10&nbsp;weeks, mice injected with COX-2-overexpressing MCF-7 and RMF-EG produced tumors with volumes approximately 200&nbsp;mm<sup>3</sup> and were randomly divided into four groups that received vehicle (DMSO), NS-398 (10&nbsp;mg/kg), L-1-methy-tryptophan (10&nbsp;mg/kg), or both inhibitors 5 times per week.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Two weeks later, animals were killed, and tumors were isolated from mice. The statistical difference between experimental groups was evaluated with repeated-measures two-way ANOVA analysis. The animal-use protocol was approved by the Institutional Animal Care and Use Committee of National Health Research Institutes.</p>
              </section><section id="Sec13" class="Section2 RenderAsSection2">
                <h3 class="Heading">Patients and statistical analysis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Paraffin-embedded human breast tumor tissues were obtained from Chi-Mei Medical Center (Tainan, Taiwan) between 1998 and 2004. The slides were stained with anti-COX-2 or anti-IDO antibodies. The COX-2 and IDO stainings were interpreted by using the H-score, defined by the following equation: H-scoreâ=âÎ£Pi (iâ+â1), as previously described [<span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>], where i is the intensity of the stained tumor cells (0 to 3+), and Pi is the percentage of stained tumor cells with various intensities. We classified tumors with cancer cells and stromal cells showing H-scores no less than the median of all scored cases as having high COX-2 and IDO expression, respectively.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The follow-up duration ranged from 5.4 to 143.6&nbsp;months, with a mean of 87.1&nbsp;months. Survival analyses for disease-specific and metastasis-free survival were performed by using Kaplan-Meier plots and compared by using the log-rank test. The correlation between COX-2 and IDO expression with clinicopathologic parameters was examined with Ï<sup>2</sup> test. <em xmlns="" class="EmphasisTypeItalic">P</em> valueâ&lt;â0.05 was considered statistically significant. This study was approved by the Research Ethics Committee of National Health Research Institutes. Written informed consent was obtained from all patients participating in this study.</p>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec14" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Results</h2><div class="js-CollapseSection"><section id="Sec15" class="Section2 RenderAsSection2">
                <h3 class="Heading">COX-2-overexpressing breast cancer cells upregulated IDO expression in co-cultured fibroblasts</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We analyzed the metabolite profile of the supernatant of RMF-EG human breast fibroblasts co-cultured with MCF-76 or COX-2-overexpressing MCF-7 cells and found that several metabolites were increased in the supernatant of COX-2-overexpressing MCF-7/RMF-EG co-culture. A peak with the m/z ratio of 209 was increased about twofold (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>A). By using Human Metabolome Database search, a candidate metabolite was predicted to be kynurenine. UPLC/MS/MS analysis demonstrated that fragmentation of kynurenine standard yielded three peaks with m/z ratio of 209, 192, and 146, which is consistent with the reported data (accession: K0009019, MassBank, [<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>]) (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>B). Significant increase of kynurenine was confirmed with an ELISA assay (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>C).<figure xmlns="" class="Figure" id="Fig1"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig1_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig1_HTML.jpg"></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 1</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Increase of IDO expression and kynurenine production in fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. (A)</strong> Metabolite profiling of the supernatant of RMF-EG fibroblasts co-cultured with MCF-7 (RMF-M) and COX-2-overexpressing MCF-7 (RMF-COX/M) cells and identified a peak with m/z ratio of 209 was increased. <strong class="EmphasisTypeBold">(B)</strong> UPLC/MS/MS fragmentation profile of the 209 (m/z) peak and the standard (L-kynurenine). <strong class="EmphasisTypeBold">(C)</strong> Increase of kynurenine in RMF-COX/M cells determined with an ELISA assay. The results from three independent assays were expressed as meanâÂ±âSEM. Statistical significance was evaluated with the Student <em class="EmphasisTypeItalic">t</em> test. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. <strong class="EmphasisTypeBold">(D)</strong> Upregulation of IDO but not TDO in RMF-COX/M cells was assayed with quantitative RT-PCR. The results from three independent assays were expressed as meanâÂ±âSEM. Statistical significance was evaluated with Student <em class="EmphasisTypeItalic">t</em> test (i). *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. Protein level was also determined with Western blotting (ii). <strong class="EmphasisTypeBold">(E)</strong> MCF-7 cells were treated without (C) or with doxycycline (DOX, 1&nbsp;Î¼g/ml) for 72&nbsp;hours to induce COX-2 expression. Protein level of COX-2 and IDO was studied with Western blotting. A 3.6-fold increase of COX-2 was found, whereas the expression of IDO was not detectable. <strong class="EmphasisTypeBold">(F)</strong> Protein level of COX-2 and IDO in MCF-7 and MDA-MB-231 cells was compared. In addition, IDO expression of RMF-EG cells co-cultured with MCF-7 or MDA-MB-231 cells was investigated.</p>
                      </div></figcaption></figure></div>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The rate-limiting enzymes in the generation of kynurenine are indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). We found a 2.5-fold of increase of IDO mRNA in RMF-EG cells co-cultured with COX-2-overexpressing MCF-7 cells, whereas the expression of TDO was not changed (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>Di). A similar increase of IDO protein level was also found (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>Dii). IDO was very low or undetectable in MCF-7- and COX-2-overexpressing MCF-7 cells, indicating that the kynurenine in the co-cultured medium was produced mainly by RMF-EG cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>E). Co-culture of the COX-2-overexpressing MDA-MB-231 cells also upregulated IDO expression in RMF-EG cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig1">1</a></span>F). These data suggest that COX-2-overexpressing breast cancer cells stimulate IDO expression and increase kynurenine secretion in co-cultured fibroblasts.</p>
              </section><section id="Sec16" class="Section2 RenderAsSection2">
                <h3 class="Heading">PGE<sub xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml">2</sub>transcriptionally elevated IDO expression in RMF-EG fibroblasts through the EP4/STAT3 signaling pathway</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We found that PGE<sub>2</sub> increased IDO mRNA and protein levels in RMF-EG cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig2">2</a></span>Ai and <span class="InternalRef"><a href="#Fig2">2</a></span>Aii). In addition, our data showed that only PGE<sub>2</sub>-alcohol (an EP4 agonist) significantly upregulated IDO expression (Figure&nbsp;<span class="InternalRef"><a href="#Fig2">2</a></span>B). Knockdown of EP4 abolished PGE<sub>2</sub>-induced increase of IDO in these cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig2">2</a></span>Ci and <span class="InternalRef"><a href="#Fig2">2</a></span>Cii). By using different <em xmlns="" class="EmphasisTypeItalic">IDO</em> deletion promoters, we demonstrated that PGE<sub>2</sub> stimulated <em xmlns="" class="EmphasisTypeItalic">IDO</em> transcription via the â1,140/-844 region from the transcription start site (see Additional file <span class="InternalRef"><a href="#MOESM2">2</a></span>: Figure S1). This region contained two potential Î³-interferon-activated sites (GASs) that could be activated by different signal transducer and activator of transcription (STAT) proteins [<span class="CitationRef"><a href="#CR21" data-toggle="citation" data-target="CR21">21</a></span>],[<span class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>]. Both STAT1 and STAT3 have been implicated in the regulation of IDO expression [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>],[<span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>].<figure xmlns="" class="Figure" id="Fig2"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig2_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig2_HTML.jpg"></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 2</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">PGE</strong><sub xmlns="http://www.w3.org/1999/xhtml">
                            <strong xmlns="" class="EmphasisTypeBold">2</strong>
                          </sub><strong class="EmphasisTypeBold">upregulated IDO expression in fibroblasts via the EP4/STAT3 pathway. (A)</strong> RMF-EG cells were treated with DMSO or PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub> (2&nbsp;Î¼<em class="EmphasisTypeItalic">M</em>) in 1% FCS medium for 48&nbsp;hours. IDO mRNA (i) and protein (ii) were determined by quantitative RT-PCR and Western blotting. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. <strong class="EmphasisTypeBold">(B)</strong> RMF-EG cells were treated with 17-phenyl-trinor-PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub> (an EP1 and EP3 receptor agonist), butaprost (an EP2 agonist), or PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>-alcohol (an EP4 agonist) for 48&nbsp;hours, and IDO expression was studied with quantitative RT-PCR. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. <strong class="EmphasisTypeBold">(C)</strong> RMF-EG cells were pretreated with EP4 shRNA for 24&nbsp;hours and then cultured with MCF-7 (RMF-M) and COX-2-overexpressing MCF-7 (RMF-COX/M) cells for another 48&nbsp;hours. (i) The IDO mRNA level was determined with quantitative RT-PCR. (ii) Protein level of IDO and EP4 was studied with Western blotting. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. <strong class="EmphasisTypeBold">(D)</strong> RMF-EG cells were pretreated with STAT3 siRNA for 24&nbsp;hours and then cultured with PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>-alcohol for another 48&nbsp;hours. Protein levels of STAT3 and IDO were determined. <strong class="EmphasisTypeBold">(E)</strong> RMF-EG cells were transfected with pcDNA or STAT3 expression vector for 48&nbsp;hours. Expression of STAT3 and IDO was studied with Western blotting.</p>
                      </div></figcaption></figure></div>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We performed a ChIP assay and found that the binding of STAT3 to <em xmlns="" class="EmphasisTypeItalic">IDO</em> promoter was increased in RMF-EG cells co-cultured with COX-2-overexpressing MCF-7 cells, whereas the binding of STAT1 was decreased (see Additional file <span class="InternalRef"><a href="#MOESM3">3</a></span>: Figure S2). Knockdown of STAT3 abolished the increase of IDO induced by the EP4 agonist in RMF-EG cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig2">2</a></span>D). Ectopic expression of STAT3 upregulated IDO (2.8-fold) in these cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig2">2</a></span>E). Thus, COX-2-overexpressing breast cancer cells upregulate IDO expression in fibroblasts through the PGE<sub>2</sub>/EP4/STAT3 pathway.</p>
              </section><section id="Sec17" class="Section2 RenderAsSection2">
                <h3 class="Heading">IDO-expressing fibroblasts enhanced the migration of breast cancer cells through downregulation of E-cadherin</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We next studied the effect of kynurenine on breast cancer cells. Kynurenine did not affect the proliferation of MCF-7 cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>A). However, kynurenine significantly increased the motility of MCF-7 and COX-2-overexpressing MCF-7 cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>B). The conditioned medium of RMF-EG fibroblasts preincubated with COX-2-overexpressing MCF-7 cells also increased the motility of MCF-7 cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>C). We used 1-methyl-L-tryptophan to inhibit IDO activity in RMF-EG fibroblasts induced by co-culture with COX2-overexpressing MCF-7 cells and found that the stimulatory effect on cell motility was blocked (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>C). These data suggested that kynurenine released by IDO-expressing fibroblasts enhanced the migration of breast cancer cells.<figure xmlns="" class="Figure" id="Fig3"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig3_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig3_HTML.jpg"></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 3</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Kynurenine induced E-cadherin ubiquitination and degradation and increased migration of breast cancer cells. (A)</strong> MCF-7 cells were treated with different concentrations of kynurenine for 48&nbsp;hours, and cellular proliferation was investigated with MTT assay. <strong class="EmphasisTypeBold">(B)</strong> MCF-7- or COX-2-overexpressing MCF-7 cells were treated with 100&nbsp;Î¼<em class="EmphasisTypeItalic">M</em> kynurenine, and cell migration was studied with transwell assays. The results from three independent assays were expressed as meanâÂ±âSEM. Statistical significance was evaluated with Student <em class="EmphasisTypeItalic">t</em> test. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. <strong class="EmphasisTypeBold">(C)</strong> RMF-EG cells were cultured in the absence or presence of IDO inhibitor 1-methyl-L-tryptophan (L-1-MT) in the lower well of the transwell unit. MCF-7- or COX-2-overexpressing MCF-7 cells were seeded in the upper well. After 24&nbsp;hours, migrated cell number was determined. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05. <strong class="EmphasisTypeBold">(D)</strong> MCF-7 cells were incubated without (â) or with (+) 100&nbsp;Î¼<em class="EmphasisTypeItalic">M</em> kynurenine for different times. Protein (i) and mRNA (ii) levels of E-cadherin were studied. <strong class="EmphasisTypeBold">(E)</strong> MCF-7 cells were incubated with kynurenine (100&nbsp;Î¼<em class="EmphasisTypeItalic">M</em>) and MG132 (proteasome inhibitor, 10&nbsp;Î¼<em class="EmphasisTypeItalic">M</em>) or chloroquine (CQ, lysosome inhibitor, 25&nbsp;Î¼<em class="EmphasisTypeItalic">M</em>) for 24&nbsp;hours. Protein level of E-cadherin was studied with Western blotting and normalized to actin. <strong class="EmphasisTypeBold">(F)</strong> Ubiquitination of E-cadherin was studied with immunoprecipitation of E-cadherin by specific antibody, and the ubiquitination status was detected with anti-ubiquitin antibody.</p>
                      </div></figcaption></figure></div>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We investigated the expression of epithelial-to-mesenchymal markers in kynurenine-treated breast cancer cells and found that E-cadherin was reduced in a time-dependent manner (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>Di). E-cadherin began to decrease around 8&nbsp;hours after addition of kynurenine, and a 70% of reduction was found at 24&nbsp;hours. However, its mRNA did not decrease substantially (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>Dii). We found that kynurenine induced degradation of E-cadherin protein via a proteasome-dependent pathway, which could be rescued by MG132 (proteasome inhibitor) but not chloroquine (lysosome inhibitor) (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>E). In addition, ubiquitination of E-cadherin protein was increased in kynurenine-treated MCF-7 cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig3">3</a></span>F). These data suggest that kynurenine induces ubiquitination and degradation of E-cadherin to promote breast cancer cell motility.</p>
              </section><section id="Sec18" class="Section2 RenderAsSection2">
                <h3 class="Heading">Kynurenine increased the degradation of E-cadherin in an AhR- and Skp2-dependent manner</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Kynurenine has been shown to be an endogenous tumor-promoting ligand of the human AhR [<span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>]. In addition, AhR is involved in the degradation of sex steroid receptors via a cullin 4B-dependent ubiquitination pathway [<span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>]. We tested whether kynurenine reduced protein stability of E-cadherin through activation of AhR and found that the binding between AhR and E-cadherin was increased in kynurenine-treated MCF-7 cells (Figure&nbsp;<span class="InternalRef"><a href="#Fig4">4</a></span>A). Interestingly, Skp2, an F-box protein of the SCF E3 ligase, was co-immunoprecipitated with AhR, and the interaction was also increased by kynurenine. We did not detect the cullin 4B protein in the complex (data not shown). This is not a cell line-specific effect, because the interaction between AhR and E-cadherin protein was also elevated in kynurenine-treated A549 cells (see Additional file <span class="InternalRef"><a href="#MOESM4">4</a></span>: Figure S3). The 3â²-methylcholanthrene (3-MC), another AhR ligand, also induced co-localization of AhR and E-cadherin at the cell membrane (Figure&nbsp;<span class="InternalRef"><a href="#Fig4">4</a></span>B). Knockdown of Skp2 reversed kynurenine-induced reduction of E-cadherin protein without affecting AhR expression (Figure&nbsp;<span class="InternalRef"><a href="#Fig4">4</a></span>C). The AhR antagonist, 3â²4â²-dimethoxyflavone (3â²4â²-DMF), also inhibited the decrease of E-cadherin induced by kynurenine (Figure&nbsp;<span class="InternalRef"><a href="#Fig4">4</a></span>D). Additionally, kynurenine-increased migration of MCF-7 cells was blocked by 3â²4â²-DMF (Figure&nbsp;<span class="InternalRef"><a href="#Fig4">4</a></span>E). These data suggest that kynurenine induces the formation of E-cadherin/AhR/Skp2 complex and causes E-cadherin degradation.<figure xmlns="" class="Figure" id="Fig4"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig4_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig4_HTML.jpg"></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 4</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Kynurenine induced E-cadherin degradation in an AhR- and Skp2-dependent pathway. (A)</strong> MCF-7 cells were incubated with kynurenine for 6&nbsp;hours, and cellular proteins were harvested. AhR protein was immunoprecipitated by specific antibody, and the binding of E-cadherin and Skp2 was studied with Western blotting. <strong class="EmphasisTypeBold">(B)</strong> Cells were incubated with kynurenine or 3-methylcholanthrene (an AhR agonist) for 6&nbsp;hours, and the co-localization of E-cadherin and AhR was studied with confocal microscopy. <strong class="EmphasisTypeBold">(C)</strong> Cells were treated with Skp2 shRNA for 24&nbsp;hours and then incubated with kynurenine for another 48&nbsp;hours. The protein levels of Skp2, E-cadherin, and AhR were determined with Western blotting and normalized to actin level. <strong class="EmphasisTypeBold">(D)</strong> Cells were incubated with kynurenine, 3â²4â²-dimethoxyflavone (3â²4â²-DMF, an AhR antagonist) or both drugs for 24&nbsp;hours. E-cadherin protein level was investigated with Western blotting. <strong class="EmphasisTypeBold">(E)</strong> Cells were also collected and subjected to migration assay. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.05.</p>
                      </div></figcaption></figure></div>
              </section><section id="Sec19" class="Section2 RenderAsSection2">
                <h3 class="Heading">COX-2 expression in breast cancer and IDO expression in stromal fibroblasts predicted poor disease-specific and metastasis-free survival</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The correlation between COX-2 expression in tumor tissues and IDO expression in CAFs was confirmed by two approaches. First, we isolated CAFs from two breast tumor tissues without or with COX-2 overexpression and found that IDO expression in CAFs was upregulated in COX-2-overexpressing tumor (see Additional file <span class="InternalRef"><a href="#MOESM5">5</a></span>: Figure S4). Second, we used immunohistochemical analysis to detect COX-2 and IDO expression in a cohort of breast cancer tissues (Figure&nbsp;<span class="InternalRef"><a href="#Fig5">5</a></span>A). COX-2 expression in tumors was positively correlated with a high IDO expression in CAFs (65 of 101, 64%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.001) (Table&nbsp;<span class="InternalRef"><a href="#Tab1">1</a></span>). COX-2 was highly expressed in stage III (19 of 24, 79%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.05), N1-N2 (61 of 85, 71%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.001), and T3-4 stage (20 of24, 83%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.05) tumor specimens. IDO expression in CAFs was significantly expressed in stage III (20 of 24, 83%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.05), N1-N2 (60 of 85, 71%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.001), and T3-4 stage (21 of 24, 88%; <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.001) tumor specimens. The disease-specific and metastasis-free survival declined significantly in patients with high COX-2 expression in breast tumors (<em xmlns="" class="EmphasisTypeItalic">P</em>â=â0.0043 and <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.0001, respectively) (Figure&nbsp;<span class="InternalRef"><a href="#Fig5">5</a></span>B and Table&nbsp;<span class="InternalRef"><a href="#Tab2">2</a></span>). Similarly, the disease-specific and metastasis-free survival declined significantly in patients with high IDO expression in CAFs (<em xmlns="" class="EmphasisTypeItalic">P</em>â=â0.0045 and <em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.0001) (Figure&nbsp;<span class="InternalRef"><a href="#Fig5">5</a></span>C and Table&nbsp;<span class="InternalRef"><a href="#Tab2">2</a></span>). More important, high COX-2 in tumors and high IDO1 expression in CAFs predicted worse disease-free and metastasis-free survivals in breast cancer patients (<em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.0001, Figure&nbsp;<span class="InternalRef"><a href="#Fig5">5</a></span>D).<figure xmlns="" class="Figure" id="Fig5"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig5_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig5_HTML.jpg"></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 5</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Coexpression of cancer COX-2 and stromal IDO predicted worse patient survival. (A)</strong> Immunohistochemical staining showed COX-2 expression in breast tumor tissues and IDO expression in tumor stroma. <strong class="EmphasisTypeBold">(B)</strong> High COX-2 expression in tumor tissues was associated with reduced disease-specific and metastasis-free survival. <strong class="EmphasisTypeBold">(C)</strong> High IDO expression in tumor stroma also was associated with reduced disease-specific and metastasis-free survival. <strong class="EmphasisTypeBold">(D)</strong> Coexpression of tumor COX-2 and stroma IDO predicted worse patient survival.</p>
                      </div></figcaption></figure></div>
                <figure id="Tab1" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 1</span>
                      <p xmlns="" class="SimplePara">
                        <strong class="EmphasisTypeBold">Correlation between Cox-2 and Ido-1 expression and various clinicopathologic factors</strong>
                      </p>
                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><thead><tr class="header"><th rowspan="2" align="left"><p xmlns="" class="SimplePara">Parameters</p></th><th rowspan="2" align="left"><p xmlns="" class="SimplePara">Category</p></th><th rowspan="2" align="left"><p xmlns="" class="SimplePara">No. of cases</p></th><th colspan="2" align="left"><p xmlns="" class="SimplePara">Cox-2 expression (tumor)</p></th><th rowspan="2" align="left"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">P</span>value</p></th><th colspan="2" align="left"><p xmlns="" class="SimplePara">Ido-1 expression (CAF)</p></th><th rowspan="2" align="left"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">P</span>value</p></th></tr><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Low exp.</p></th><th align="left"><p xmlns="" class="SimplePara">High exp.</p></th><th align="left"><p xmlns="" class="SimplePara">Low exp.</p></th><th align="left"><p xmlns="" class="SimplePara">High exp.</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Age (years)</p></td><td align="left"><p xmlns="" class="SimplePara">&lt;60&nbsp;years</p></td><td align="left"><p xmlns="" class="SimplePara">141</p></td><td align="left"><p xmlns="" class="SimplePara">73</p></td><td align="left"><p xmlns="" class="SimplePara">68</p></td><td align="left"><p xmlns="" class="SimplePara">0.444</p></td><td align="left"><p xmlns="" class="SimplePara">69</p></td><td align="left"><p xmlns="" class="SimplePara">72</p></td><td align="left"><p xmlns="" class="SimplePara">0.647</p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara"><span class="stix">â§</span>60&nbsp;years</p></td><td align="left"><p xmlns="" class="SimplePara">61</p></td><td align="left"><p xmlns="" class="SimplePara">28</p></td><td align="left"><p xmlns="" class="SimplePara">33</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">32</p></td><td align="left"><p xmlns="" class="SimplePara">29</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Primary tumor (T)</p></td><td align="left"><p xmlns="" class="SimplePara">T1</p></td><td align="left"><p xmlns="" class="SimplePara">82</p></td><td align="left"><p xmlns="" class="SimplePara">45</p></td><td align="left"><p xmlns="" class="SimplePara">37</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.002</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">44</p></td><td align="left"><p xmlns="" class="SimplePara">38</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.001</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">T2</p></td><td align="left"><p xmlns="" class="SimplePara">96</p></td><td align="left"><p xmlns="" class="SimplePara">52</p></td><td align="left"><p xmlns="" class="SimplePara">44</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">54</p></td><td align="left"><p xmlns="" class="SimplePara">42</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">T3-4</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">21</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Nodal status (N)</p></td><td align="left"><p xmlns="" class="SimplePara">N0</p></td><td align="left"><p xmlns="" class="SimplePara">117</p></td><td align="left"><p xmlns="" class="SimplePara">77</p></td><td align="left"><p xmlns="" class="SimplePara">40</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.001</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">76</p></td><td align="left"><p xmlns="" class="SimplePara">41</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.001</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">N1-N2</p></td><td align="left"><p xmlns="" class="SimplePara">85</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left"><p xmlns="" class="SimplePara">61</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">25</p></td><td align="left"><p xmlns="" class="SimplePara">60</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Stage</p></td><td align="left"><p xmlns="" class="SimplePara">I</p></td><td align="left"><p xmlns="" class="SimplePara">63</p></td><td align="left"><p xmlns="" class="SimplePara">37</p></td><td align="left"><p xmlns="" class="SimplePara">26</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.006</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">37</p></td><td align="left"><p xmlns="" class="SimplePara">26</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.002</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">II</p></td><td align="left"><p xmlns="" class="SimplePara">115</p></td><td align="left"><p xmlns="" class="SimplePara">59</p></td><td align="left"><p xmlns="" class="SimplePara">56</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">60</p></td><td align="left"><p xmlns="" class="SimplePara">55</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">III</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left"><p xmlns="" class="SimplePara">5</p></td><td align="left"><p xmlns="" class="SimplePara">19</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Histologic grade</p></td><td align="left"><p xmlns="" class="SimplePara">Grade I</p></td><td align="left"><p xmlns="" class="SimplePara">18</p></td><td align="left"><p xmlns="" class="SimplePara">13</p></td><td align="left"><p xmlns="" class="SimplePara">5</p></td><td align="left"><p xmlns="" class="SimplePara">0.122</p></td><td align="left"><p xmlns="" class="SimplePara">15</p></td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.003</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Grade II</p></td><td align="left"><p xmlns="" class="SimplePara">141</p></td><td align="left"><p xmlns="" class="SimplePara">69</p></td><td align="left"><p xmlns="" class="SimplePara">72</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">71</p></td><td align="left"><p xmlns="" class="SimplePara">70</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Grade III</p></td><td align="left"><p xmlns="" class="SimplePara">43</p></td><td align="left"><p xmlns="" class="SimplePara">19</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">15</p></td><td align="left"><p xmlns="" class="SimplePara">28</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">CAF Ido-1 expression</p></td><td align="left"><p xmlns="" class="SimplePara">Low Exp. (&lt;medium)</p></td><td align="left"><p xmlns="" class="SimplePara">101</p></td><td align="left"><p xmlns="" class="SimplePara">65</p></td><td align="left"><p xmlns="" class="SimplePara">35</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.001</strong>
                          </p></td><td align="left">&nbsp;</td><td align="left">&nbsp;</td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">High Exp. (<span class="stix">â§</span>medium)</p></td><td align="left"><p xmlns="" class="SimplePara">101</p></td><td align="left"><p xmlns="" class="SimplePara">35</p></td><td align="left"><p xmlns="" class="SimplePara">65</p></td><td align="left">&nbsp;</td><td align="left">&nbsp;</td><td align="left">&nbsp;</td><td align="left">&nbsp;</td></tr></tbody></table></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                    <p xmlns="" class="SimplePara">Bold figures, Statistically significant.</p>
                  </div></figure>
                <figure id="Tab2" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 2</span>
                      <p xmlns="" class="SimplePara">
                        <strong class="EmphasisTypeBold">Univariate log-rank analysis for disease-specific survival and metastasis-free survival</strong>
                      </p>
                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><colgroup><col align="left"></colgroup><thead><tr class="header"><th rowspan="2" align="left"><p xmlns="" class="SimplePara">Parameters</p></th><th rowspan="2" align="left"><p xmlns="" class="SimplePara">Category</p></th><th rowspan="2" align="left"><p xmlns="" class="SimplePara">No. of case</p></th><th colspan="2" align="left"><p xmlns="" class="SimplePara">DSS</p></th><th colspan="2" align="left"><p xmlns="" class="SimplePara">MeFS</p></th></tr><tr class="header"><th align="left"><p xmlns="" class="SimplePara">No. of events</p></th><th align="left"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">P</span>value</p></th><th align="left"><p xmlns="" class="SimplePara">No. of events</p></th><th align="left"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">P</span>value</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Age (years)</p></td><td align="left"><p xmlns="" class="SimplePara">&lt;60&nbsp;years</p></td><td align="left"><p xmlns="" class="SimplePara">141</p></td><td align="left"><p xmlns="" class="SimplePara">13</p></td><td align="left"><p xmlns="" class="SimplePara">0.9804</p></td><td align="left"><p xmlns="" class="SimplePara">41</p></td><td align="left"><p xmlns="" class="SimplePara">0.7650</p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara"><span class="stix">â§</span>60&nbsp;years</p></td><td align="left"><p xmlns="" class="SimplePara">61</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">16</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Primary tumor (T)</p></td><td align="left"><p xmlns="" class="SimplePara">T1</p></td><td align="left"><p xmlns="" class="SimplePara">82</p></td><td align="left"><p xmlns="" class="SimplePara">5</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.0283</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">9</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.0001</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">T2</p></td><td align="left"><p xmlns="" class="SimplePara">96</p></td><td align="left"><p xmlns="" class="SimplePara">10</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">34</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">T3-4</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left"><p xmlns="" class="SimplePara">2</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">14</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Nodal status (N)</p></td><td align="left"><p xmlns="" class="SimplePara">N0</p></td><td align="left"><p xmlns="" class="SimplePara">117</p></td><td align="left"><p xmlns="" class="SimplePara">7</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.0079</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">19</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.0001</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">N1-2</p></td><td align="left"><p xmlns="" class="SimplePara">85</p></td><td align="left"><p xmlns="" class="SimplePara">10</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">38</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Stage</p></td><td align="left"><p xmlns="" class="SimplePara">I</p></td><td align="left"><p xmlns="" class="SimplePara">63</p></td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.0001</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">5</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.0001</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">II</p></td><td align="left"><p xmlns="" class="SimplePara">115</p></td><td align="left"><p xmlns="" class="SimplePara">10</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">38</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">III</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">14</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Histologic grade</p></td><td align="left"><p xmlns="" class="SimplePara">Grade I</p></td><td align="left"><p xmlns="" class="SimplePara">18</p></td><td align="left"><p xmlns="" class="SimplePara">0</p></td><td align="left"><p xmlns="" class="SimplePara">0.2066</p></td><td align="left"><p xmlns="" class="SimplePara">1</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.0269</strong>
                          </p></td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Grade II</p></td><td align="left"><p xmlns="" class="SimplePara">141</p></td><td align="left"><p xmlns="" class="SimplePara">15</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">41</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Grade III</p></td><td align="left"><p xmlns="" class="SimplePara">43</p></td><td align="left"><p xmlns="" class="SimplePara">2</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">15</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Cox-2 expression</p></td><td align="left"><p xmlns="" class="SimplePara">Low Exp (&lt;medium)</p></td><td align="left"><p xmlns="" class="SimplePara">101</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.0043</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">15</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.0001</strong>
                          </p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">(Tumor)</p></td><td align="left"><p xmlns="" class="SimplePara">High Exp (<span class="stix">â§</span>medium)</p></td><td align="left"><p xmlns="" class="SimplePara">101</p></td><td align="left"><p xmlns="" class="SimplePara">13</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">42</p></td><td align="left">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Ido-1 expression</p></td><td align="left"><p xmlns="" class="SimplePara">Low Exp (&lt;medium)</p></td><td align="left"><p xmlns="" class="SimplePara">101</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">0.0045</strong>
                          </p></td><td align="left"><p xmlns="" class="SimplePara">9</p></td><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">&lt;0.0001</strong>
                          </p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">(CAF)</p></td><td align="left"><p xmlns="" class="SimplePara">High Exp (<span class="stix">â§</span>medium)</p></td><td align="left"><p xmlns="" class="SimplePara">101</p></td><td align="left"><p xmlns="" class="SimplePara">13</p></td><td align="left">&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">48</p></td><td align="left">&nbsp;</td></tr></tbody></table></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                    <p xmlns="" class="SimplePara">Bold figures, Statistically significant.</p>
                  </div></figure>
              </section><section id="Sec20" class="Section2 RenderAsSection2">
                <h3 class="Heading">COX-2 and IDO inhibitors suppressed growth of COX-2-overexpressing breast tumors <em class="EmphasisTypeItalic">in vivo</em></h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The effect of COX-2 and IDO inhibitors was evaluated in an orthotopic model. Inoculation of MCF-7/RMF-EG- or COX-2-overexpressing MCF-7/RMF-EG cell mixture induced tumors in nude mice primed with 17Î²-estradiol injection (Figure&nbsp;<span class="InternalRef"><a href="#Fig6">6</a></span>A). Tumor growth was higher in the COX-2-overexpressing MCF-7/RMF-EG group, and a 2.4-fold of increase of tumor volume was detected at 10&nbsp;weeks (<em xmlns="" class="EmphasisTypeItalic">P</em>â&lt;â0.01). The COX-2-overexpressing MCF-7/RMF-EG group was randomly divided into four subgroups (<em xmlns="" class="EmphasisTypeItalic">n</em>â=â3). Intratumoral injection of vehicle (DMSO, control), 10&nbsp;mg/kg of NS398, 10&nbsp;mg/kg of 1-methyl-L-tryptophan, or both inhibitors was conducted, and treatment was continuous for another 2&nbsp;weeks. As shown in Figure&nbsp;<span class="InternalRef"><a href="#Fig6">6</a></span>B, tumor volume of the groups treated with NS398 or 1-methyl-L-tryptophan was smaller than that of the control group. Co-treatment of COX-2 and IDO inhibitor induced a more obvious reduction in tumor size, although it did not show an additive effect.<figure xmlns="" class="Figure" id="Fig6"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig6_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_Fig6_HTML.jpg"></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 6</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Inhibition of tumor growth by COX-2 and IDO inhibitors</strong> <span class="EmphasisTypeBoldItalic">in vivo</span> <strong class="EmphasisTypeBold">. (A)</strong> MCF-7 or MCF-7-COX2 (8âÃâ10<sup xmlns="http://www.w3.org/1999/xhtml">6</sup>) cells mixed with RMF-EG (6âÃâ10<sup xmlns="http://www.w3.org/1999/xhtml">6</sup>) cells were inoculated into the fourth mammary fat pads of 6-week-old female nude mice. Before inoculation of the cancer cell/fibroblast mixture, all mice were primed with 6&nbsp;mg/kg of 17Î²-estradiol twice a week for 3&nbsp;weeks. Measurement of tumor growth was begun at 4&nbsp;weeks after injection, and tumor volume was continuously monitored. The difference between the groups was evaluated by repeated measures two-way ANOVA analysis. n.s., no significance. *<em class="EmphasisTypeItalic">P</em>â&lt;â0.01. <strong class="EmphasisTypeBold">(B)</strong> After 10&nbsp;weeks, mice injected with MCF-COX-2 and RMF-EG cells were randomly divided into four groups that received vehicle (DMSO), NS-398 (10&nbsp;mg/kg), L-1-methy-tryptophan (10&nbsp;mg/kg), or both inhibitors 5 times per week. Two weeks later, animals were killed, and tumors were isolated from mice.</p>
                      </div></figcaption></figure></div>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec21" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Discussion</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Previous studies demonstrated that IDO overexpression increases the secretion of kynurenine to inhibit effect T cells to promote immune escape and tumor progression in various human cancers [<span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>]-â[<span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>]. The expression of IDO in cancer stroma has not been clarified. In addition, the clinical significance of stromal IDO is unclear.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In this study, we provide evidence that COX-2-overexpressing breasts cancer cells may secrete PGE<sub>2</sub> to induce IDO expression and kynurenine production in stromal fibroblasts. In addition, we show that kynurenine in the coculture-conditioned medium is produced mainly by CAFs because IDO is not induced by COX-2 overexpression in MCF-7 cells. An important upstream regulator of IDO is interferon-Î³. Yoshida <em xmlns="" class="EmphasisTypeItalic">et al</em>. [<span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>] first reported that the pulmonary IDO was induced in the mouse after intraperitoneal administration of bacterial endotoxin or during <em xmlns="" class="EmphasisTypeItalic">in vivo</em> virus infection, and this induction was triggered by interferon-Î³ [<span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>]. Because interferon-Î³ exhibits antitumor activity on various cancers <em xmlns="" class="EmphasisTypeItalic">in vitro</em> and <em xmlns="" class="EmphasisTypeItalic">in vivo</em>, it is unlikely that COX-2-overexpressing cancer cells produce interferon-Î³ to stimulate stromal IDO. For the first time, we show that cancer cell-produced PGE<sub>2</sub> transcriptionally upregulates IDO expression through the EP4/STAT3 signaling pathway. <em xmlns="" class="EmphasisTypeItalic">In vivo</em> binding of STAT3 to <em xmlns="" class="EmphasisTypeItalic">IDO</em> gene promoter is confirmed by ChIP assay. Additionally, knockdown of STAT3 totally abolishes EP4 agonist-induced IDO expression. These data suggest that <em xmlns="" class="EmphasisTypeItalic">IDO</em> is a direct transcriptional target of STAT3.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">An unresolved question is why PGE<sub>2</sub> stimulates IDO expression in stromal fibroblasts but not in breast cancer cells, because both cell types express EP4 receptor [<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>] and data not shown]. We are aware that the binding of STAT1 to <em xmlns="" class="EmphasisTypeItalic">IDO</em> promoter is reduced by PGE<sub>2</sub> (Additional file <span class="InternalRef"><a href="#MOESM3">3</a></span>: Figure S2); therefore, it is possible that the expression level of STAT1 and STAT3 and the competition between these two STATs may determine the response of cells to PGE<sub>2</sub> stimulation.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The concept of oncometabolite was established by the studies that mutations of isocitrate dehydrogenase 1 (IDH1) and IDH2 generate a novel metabolite 2-hydroxyglutarate (2-HG) that exhibits oncogenic activity in acute myeloid leukemia and glioma [<span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>],[<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>]. Subsequently, 2-HG was shown to be a competitive inhibitor of Î±-ketoglutarate-dependent dioxygenases and inhibits histone demethylases like Tet methylcytosine dioxygenase 2 (TET2) to change promoter methylation and gene transcription [<span class="CitationRef"><a href="#CR34" data-toggle="citation" data-target="CR34">34</a></span>],[<span class="CitationRef"><a href="#CR35" data-toggle="citation" data-target="CR35">35</a></span>]. Kynurenine represents another oncometabolite, which acts as an immunosuppressor to create a favorable microenvironment for tumor formation and metastasis [<span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>]. A recent study demonstrated that the tryptophan catabolism enzyme TDO is overexpressed in human brain tumors, and elevated secretion of kynurenine promotes cell migration via an AhR-dependent pathway [<span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">However, the underlying mechanism by which kynurenine increases cell motility is still unclear. After screening of the EMT markers, we found that E-cadherin is decreased in kynurenine-treated breast cancer cells, and AhR is involved in this process. AhR has been shown to integrate as a component of a novel Cul4B ubiquitin E3 ligase complex and participated in the degradation of sex steroid receptors [<span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>]. We demonstrated that kynurenine increases the interaction between AhR and E-cadherin, and the AhR/E-cadherin complex also contains Skp2, an F-box protein of SCF E3 ligase. The formation of the E-cadherin/AhR/Skp2 complex and ubiquitination of E-cadherin induced by kynurenine is also detectable in A549 cells, indicating a general mechanism of kynurenine-induced proteolysis of E-cadherin in different cancer cells. Our results provide a novel oncometabolite function of kynurenine to enhance cancer cell migration by degrading E-cadherin.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The clinical validation of tumor COX-2 and stromal IDO in this study is important to verify the cancer-stroma interplay in cancer progression. Many histopathologic studies investigated the expression of two specific genes in the epithelial components of tumor tissues to show their association and to demonstrate the vertical regulation of these two genes. The correlation and clinical significance of genes separately expressed in tumor and stroma have received little attention.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">However, the gene signatures in CAFs may provide more information than originally thought. West <em xmlns="" class="EmphasisTypeItalic">et al</em>. [<span class="CitationRef"><a href="#CR37" data-toggle="citation" data-target="CR37">37</a></span>] first classified two stromal gene signature from tumors with solitary fibrous tumor (SFT) and desmoids-type fibromatosis (DTF) features and showed that patients with the expression of DTF had a favorable clinical outcome. Their subsequent study by using public databases and immunohistochemical approaches suggested that DTF fibroblast signature is a common tumor stroma signature in different types of cancers [<span class="CitationRef"><a href="#CR38" data-toggle="citation" data-target="CR38">38</a></span>]. Mercier <em xmlns="" class="EmphasisTypeItalic">et al</em>. [<span class="CitationRef"><a href="#CR39" data-toggle="citation" data-target="CR39">39</a></span>] identified a hyperproliferative gene signature in CAFs and found that breast cancer patients with this signature had a poor prognosis with tamoxifen monotherapy and a great reduction in recurrence-free survival [<span class="CitationRef"><a href="#CR39" data-toggle="citation" data-target="CR39">39</a></span>]. By using a mouse model of squamous skin carcinogenesis, Erez [<span class="CitationRef"><a href="#CR40" data-toggle="citation" data-target="CR40">40</a></span>] demonstrated that carcinoma cells could educate CAFs to express proinflammatory genes to promote macrophage recruitment, neovascularization, and tumor growth. Additionally, this gene signature was also evident in mammary and pancreatic tumors in mice and in human cancers. By using metabolomics, molecular, and pathological approaches, we revealed that induction of stromal IDO by COX-2-overexpressing breast cancer cells promotes tumor progression and predicts poor patient survival.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Results of our animal study also clearly demonstrate the anticancer effect of COX-2 and IDO inhibitor on COX-2-overexpressing breast cancer <em xmlns="" class="EmphasisTypeItalic">in vivo</em>. A combination of IDO and COX-2 inhibitor exhibits a more obvious effect on the inhibition of tumor growth. However, we did not find an additive effect. This can be because (a) the number of animals in each group is small, and (b) inhibition of COX-2 in cancer cells will attenuate stromal IDO expression, which reduces the anticancer activity of IDO inhibitor. Additional experiments are needed to clarify this issue.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec22" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Conclusion</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">By using a metabolomics approach, we identified potential oncometabolites involved in the crosstalk between COX-2-overexpressing breast cancer cells and fibroblasts. Molecular study elucidates the underlying mechanism by which this cancer/stroma interplay via COX-2 and IDO promotes tumor progression. In addition, pathological investigation validates the importance of cancer COX-2 and stromal IDO in the prediction of the patientâs survival. Simultaneous targeting of COX-2 and IDO may be a new strategy for breast cancer treatment.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec23" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Additional files</h2><div class="js-CollapseSection"></div></section>
          <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="AbbreviationGroup"><h2 class="Heading js-ToggleCollapseSection">Abbreviations</h2><div class="js-CollapseSection"><div class="DefinitionList">
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>2-HG:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">2-hydroxyglutarate</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>3â²4â²-DMF:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">3â²4â²-dimethoxyflavone</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>3-MC:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">3â²-methylcholanthrene</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>AhR:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">aryl hydrocarbon receptor</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>CAF:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">cancer-associated fibroblast</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>CXCL12:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">chemokine (C-X-C motif) ligand 12</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>CXCL14:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">chemokine (C-X-C motif) ligand 14</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>DAPI:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">4â²,6-diamidino-2-phenylindole</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>DTF:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">desmoid-type fibromatosis</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>ELISA:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">enzyme-linked immunosorbent assay</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>EMT:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">epithelial-mesenchymal transition</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>EP4:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">prostaglandin E receptor 4</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>IDH:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">isocitrate dehydrogenase</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>IDO:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">indoleamine 2,3-dioxygenase</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>MMP:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">matrix metalloproteinase</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>NF-ÎºB:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">nuclear factor kappa-light-chain-enhancer of activated B cells</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>PGE<sub xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml">2</sub>:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">prostaglandin E<sub>2</sub></p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>SDF-1:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">stromal cell-derived factor 1</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>SFT:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">solitary fibrous tumor</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>shRNA:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">short-hairpin RNA</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>Skp2:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">S-phase kinase-associated protein 2</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>STAT3:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">signal transducer and activator of transcription 3</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>TET2:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Tet methylcytosine dioxygenase 2</p>
                  </dd></dl>
                <dl class="DefinitionListEntry"><dt class="Term"><dfn>UPLC:&nbsp;</dfn></dt><dd class="Description">
                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">ultraperformance liquid chromatography</p>
                  </dd></dl>
              </div></div></section><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="Declarations"><h2 class="Heading js-ToggleCollapseSection">
              Declarations
            </h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Acknowledgments"><h3 xmlns="" class="Heading">Acknowledgements</h3><p xmlns="" class="SimplePara">We deeply thank Dr. Wu KK for his continuous support and encouragement. We also thank Ms. Pei-Yung Nien for the isolation of primary CAFs and Dr. Delphine Allorge and Dr. Marion Soichot for providing human IDO promoter. This study was supported by grants from National Science Council (NSC 101-2321-B-400-003 and NSC 102-2321-B-400-003) and MOHW103-TD-B-111-05 from Excellence for Cancer Research Center Grant, the Ministry of Health and Welfare.</p></div><aside class="Appendix" id="App1">
              
                <h3 class="Heading">Electronic supplementary material</h3><div id="widgetContainer"></div>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">
                  <div class="MediaObject" id="MOESM1">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM1_ESM.doc">13058_2014_410_MOESM1_ESM.doc</a>
                          <span xmlns="" class="SimplePara">Additional file 1: Supplementary materials and methods.(DOC 50 KB)</span>
                        </div></div>
                  </div>
                  <div class="MediaObject" id="MOESM2">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM2_ESM.tiff">13058_2014_410_MOESM2_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Additional file 2: Figure S1.: PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub> stimulated <em class="EmphasisTypeItalic">IDO</em> promoter activity. Different <em class="EmphasisTypeItalic">IDO</em> promoter constructs were transfected into MCF-7 cells and stimulated by PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>. Promoter assay indicated that PGE<sub xmlns="http://www.w3.org/1999/xhtml">2</sub> activated <em class="EmphasisTypeItalic">IDO</em> via the â1140/-844 promoter region. (TIFF 118 KB)</span>
                        </div></div>
                  </div>
                  <div class="MediaObject" id="MOESM3">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM3_ESM.tiff">13058_2014_410_MOESM3_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Additional file 3: Figure S2.: <em class="EmphasisTypeItalic">In vivo</em> binding of STAT3 on <em class="EmphasisTypeItalic">IDO</em> gene promoter in EMF-EG fibroblasts and its regulation by co-culture of COX-2-overexpressing MCF7 cells. ChIP assay demonstrated that the binding of STAT3 to <em class="EmphasisTypeItalic">IDO</em> promoter was increased, whereas the binding of STAT1 was reduced in EMF-EG fibroblasts after co-culture with COX-2-overexpressing MCF-7 cells. (TIFF 93 KB)</span>
                        </div></div>
                  </div>
                  <div class="MediaObject" id="MOESM4">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM4_ESM.tiff">13058_2014_410_MOESM4_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Additional file 4: Figure S3.: Kynurenine induced the formation of E-cadherin/AhR/Skp2 complex in A549 lung cancer cells. A549 cells were treated without (â) or with (+) kynurenine, and the interaction between E-cadherin and AhR or Skp2 was studied by immunoprecipitation and Western blotting. (TIFF 162 KB)</span>
                        </div></div>
                  </div>
                  <div class="MediaObject" id="MOESM5">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM5_ESM.tiff">13058_2014_410_MOESM5_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Additional file 5: Figure S4.: IDO expression in cancer-associated fibroblasts (CAFs) was increased in COX-2-overexpressing breast cancer. (TIFF 153 KB)</span>
                        </div></div>
                  </div>
                </div>
              
              
                
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Below are the links to the authorsâ original submitted files for images.<div class="MediaObject" id="MOESM6">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM6_ESM.gif">13058_2014_410_MOESM6_ESM.gif</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 1</span>
                        </div></div>
                  </div><div class="MediaObject" id="MOESM7">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM7_ESM.gif">13058_2014_410_MOESM7_ESM.gif</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 2</span>
                        </div></div>
                  </div><div class="MediaObject" id="MOESM8">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM8_ESM.gif">13058_2014_410_MOESM8_ESM.gif</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 3</span>
                        </div></div>
                  </div><div class="MediaObject" id="MOESM9">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM9_ESM.gif">13058_2014_410_MOESM9_ESM.gif</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 4</span>
                        </div></div>
                  </div><div class="MediaObject" id="MOESM10">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM10_ESM.gif">13058_2014_410_MOESM10_ESM.gif</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 5</span>
                        </div></div>
                  </div><div class="MediaObject" id="MOESM11">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM11_ESM.gif">13058_2014_410_MOESM11_ESM.gif</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 6</span>
                        </div></div>
                  </div><div class="MediaObject" id="MOESM12">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs13058-014-0410-1/MediaObjects/13058_2014_410_MOESM12_ESM.tiff">13058_2014_410_MOESM12_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 7</span>
                        </div></div>
                  </div></div>
              
            </aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Competing interests</h3><p xmlns="" class="SimplePara">The authors declare that they have no competing interests.</p></aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Authorsâ contributions</h3><p xmlns="" class="SimplePara">JY conducted cell culture, biochemical, and molecular biology assays and prepared the draft of the manuscript. CF did IHC study and pathological analysis and helped to draft the manuscript. CC performed metabolomics study and data analysis and helped to draft the manuscript. KK participated in the design of the study and helped to draft the manuscript. MF conceived of the study and participated in the preparation of primary cancer-associated fibroblasts. WC conceived of the study and participated in the design of the study and wrote the manuscript. All authors read and approved the final manuscript.</p></aside></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 Affiliations" id="Aff"><h2 class="Heading js-ToggleCollapseSection">Authorsâ Affiliations</h2><div class="js-CollapseSection"><div class="Affiliation" id="Aff1"><span class="AffiliationNumber">(1)</span><div class="AffiliationText">National Institute of Cancer Research, National Health Research Institutes</div></div><div class="Affiliation" id="Aff2"><span class="AffiliationNumber">(2)</span><div class="AffiliationText">Department of Pathology, Chi-Mei Foundation Medical Center</div></div><div class="Affiliation" id="Aff3"><span class="AffiliationNumber">(3)</span><div class="AffiliationText">Institute of Cellular and System Medicine, National Health Research Institutes</div></div><div class="Affiliation" id="Aff4"><span class="AffiliationNumber">(4)</span><div class="AffiliationText">Department of Surgery, College of Medicine, Kaohsiung Medical University</div></div><div class="Affiliation" id="Aff5"><span class="AffiliationNumber">(5)</span><div class="AffiliationText">Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital</div></div><div class="Affiliation" id="Aff6"><span class="AffiliationNumber">(6)</span><div class="AffiliationText">Cancer Center, Kaohsiung Medical University Hospital</div></div><div class="Affiliation" id="Aff7"><span class="AffiliationNumber">(7)</span><div class="AffiliationText">Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University</div></div></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 SectionTypeMaterialsAndMethods" id="Bib1"><h2 class="Heading js-ToggleCollapseSection">References</h2><div class="js-CollapseSection"><ol class="BibliographyWrapper"><li class="Citation"><cite class="CitationContent" id="CR1">Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999, 18: 7908-7916.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/sj.onc.1203286"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10630643"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20role%20of%20cyclooxygenases%20in%20inflammation%2C%20cancer%2C%20and%20development&amp;author=CS.%20Williams&amp;author=M.%20Mann&amp;author=RN.%20DuBois&amp;journal=Oncogene&amp;volume=18&amp;pages=7908-7916&amp;publication_year=1999"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR2">Terzic J, Grivennikov S, Karin E, Karin M: Inflammation and colon cancer. Gastroenterology. 2010, 138: 2101-2114. e2105<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1053/j.gastro.2010.01.058"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20420949"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Inflammation%20and%20colon%20cancer&amp;author=J.%20Terzic&amp;author=S.%20Grivennikov&amp;author=E.%20Karin&amp;author=M.%20Karin&amp;journal=Gastroenterology&amp;volume=138&amp;pages=2101-2114&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR3">Howe LR: Inflammation and breast cancer: cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007, 9: 210-<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1186/bcr1678"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17640394"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206709"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Inflammation%20and%20breast%20cancer%3A%20cyclooxygenase%2Fprostaglandin%20signaling%20and%20breast%20cancer&amp;author=LR.%20Howe&amp;journal=Breast%20Cancer%20Res&amp;volume=9&amp;pages=210&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR4">Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62: 632-635.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11830510"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20significance%20of%20elevated%20cyclooxygenase-2%20expression%20in%20breast%20cancer&amp;author=A.%20Ristimaki&amp;author=A.%20Sivula&amp;author=J.%20Lundin&amp;author=M.%20Lundin&amp;author=T.%20Salminen&amp;author=C.%20Haglund&amp;author=H.%20Joensuu&amp;author=J.%20Isola&amp;journal=Cancer%20Res&amp;volume=62&amp;pages=632-635&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR5">Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W, Kiesel L: Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol. 2003, 129: 375-382.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1007/s00432-003-0459-1"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12884024"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Analysis%20of%20cyclooxygenase-2%20expression%20in%20human%20breast%20cancer%3A%20high%20throughput%20tissue%20microarray%20analysis&amp;author=P.%20Wulfing&amp;author=R.%20Diallo&amp;author=C.%20Muller&amp;author=C.%20Wulfing&amp;author=C.%20Poremba&amp;author=A.%20Heinecke&amp;author=A.%20Rody&amp;author=RR.%20Greb&amp;author=W.%20Bocker&amp;author=L.%20Kiesel&amp;journal=J%20Cancer%20Res%20Clin%20Oncol&amp;volume=129&amp;pages=375-382&amp;publication_year=2003"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR6">Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 2003, 9: 2651-2656.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12855643"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Correlation%20between%20cyclooxygenase-2%20expression%20and%20angiogenesis%20in%20human%20breast%20cancer&amp;author=G.%20Davies&amp;author=J.%20Salter&amp;author=M.%20Hills&amp;author=LA.%20Martin&amp;author=N.%20Sacks&amp;author=M.%20Dowsett&amp;journal=Clin%20Cancer%20Res&amp;volume=9&amp;pages=2651-2656&amp;publication_year=2003"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR7">Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996, 88: 988-993.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1093/jnci/88.14.988"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8667430"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prospective%20study%20of%20regular%20aspirin%20use%20and%20the%20risk%20of%20breast%20cancer&amp;author=KM.%20Egan&amp;author=MJ.%20Stampfer&amp;author=E.%20Giovannucci&amp;author=BA.%20Rosner&amp;author=GA.%20Colditz&amp;journal=J%20Natl%20Cancer%20Inst&amp;volume=88&amp;pages=988-993&amp;publication_year=1996"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR8">Arun B, Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004, 31: 22-29.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1053/j.seminoncol.2004.03.042"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15179621"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20role%20of%20COX-2%20inhibition%20in%20breast%20cancer%20treatment%20and%20prevention&amp;author=B.%20Arun&amp;author=P.%20Goss&amp;journal=Semin%20Oncol&amp;volume=31&amp;pages=22-29&amp;publication_year=2004"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR9">Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A. 2004, 101: 591-596.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1073/pnas.2535911100"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14688410"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Role%20of%20prostaglandin%20E2-dependent%20angiogenic%20switch%20in%20cyclooxygenase%202-induced%20breast%20cancer%20progression&amp;author=SH.%20Chang&amp;author=CH.%20Liu&amp;author=R.%20Conway&amp;author=DK.%20Han&amp;author=K.%20Nithipatikom&amp;author=OC.%20Trifan&amp;author=TF.%20Lane&amp;author=T.%20Hla&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=101&amp;pages=591-596&amp;publication_year=2004"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR10">Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002, 62: 5405-5407.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12359744"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Celecoxib%2C%20a%20selective%20cyclooxygenase%202%20inhibitor%2C%20protects%20against%20human%20epidermal%20growth%20factor%20receptor%202%20%28HER-2%29%2Fneu-induced%20breast%20cancer&amp;author=LR.%20Howe&amp;author=K.%20Subbaramaiah&amp;author=J.%20Patel&amp;author=JL.%20Masferrer&amp;author=A.%20Deora&amp;author=C.%20Hudis&amp;author=HT.%20Thaler&amp;author=WJ.%20Muller&amp;author=B.%20Du&amp;author=AM.%20Brown&amp;author=AJ.%20Dannenberg&amp;journal=Cancer%20Res&amp;volume=62&amp;pages=5405-5407&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR11">Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000, 60: 2101-2103.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10786667"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Chemoprevention%20of%20breast%20cancer%20in%20rats%20by%20celecoxib%2C%20a%20cyclooxygenase%202%20inhibitor&amp;author=RE.%20Harris&amp;author=GA.%20Alshafie&amp;author=H.%20Abou-Issa&amp;author=K.%20Seibert&amp;journal=Cancer%20Res&amp;volume=60&amp;pages=2101-2103&amp;publication_year=2000"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR12">Aboussekhra A: Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int J Dev Biol. 2011, 55: 841-849.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1387/ijdb.113362aa"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22161840"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Role%20of%20cancer-associated%20fibroblasts%20in%20breast%20cancer%20development%20and%20prognosis&amp;author=A.%20Aboussekhra&amp;journal=Int%20J%20Dev%20Biol&amp;volume=55&amp;pages=841-849&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR13">Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121: 335-348.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.cell.2005.02.034"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15882617"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Stromal%20fibroblasts%20present%20in%20invasive%20human%20breast%20carcinomas%20promote%20tumor%20growth%20and%20angiogenesis%20through%20elevated%20SDF-1%2FCXCL12%20secretion&amp;author=A.%20Orimo&amp;author=PB.%20Gupta&amp;author=DC.%20Sgroi&amp;author=F.%20Arenzana-Seisdedos&amp;author=T.%20Delaunay&amp;author=R.%20Naeem&amp;author=VJ.%20Carey&amp;author=AL.%20Richardson&amp;author=RA.%20Weinberg&amp;journal=Cell&amp;volume=121&amp;pages=335-348&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR14">Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004, 6: 17-32.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2004.06.010"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15261139"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Molecular%20characterization%20of%20the%20tumor%20microenvironment%20in%20breast%20cancer&amp;author=M.%20Allinen&amp;author=R.%20Beroukhim&amp;author=L.%20Cai&amp;author=C.%20Brennan&amp;author=J.%20Lahti-Domenici&amp;author=H.%20Huang&amp;author=D.%20Porter&amp;author=M.%20Hu&amp;author=L.%20Chin&amp;author=A.%20Richardson&amp;author=S.%20Schnitt&amp;author=WR.%20Sellers&amp;author=K.%20Polyak&amp;journal=Cancer%20Cell&amp;volume=6&amp;pages=17-32&amp;publication_year=2004"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR15">Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K: Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A. 2009, 106: 3372-3377.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1073/pnas.0813306106"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19218449"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642666"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Role%20of%20COX-2%20in%20epithelial-stromal%20cell%20interactions%20and%20progression%20of%20ductal%20carcinoma%20in%20situ%20of%20the%20breast&amp;author=M.%20Hu&amp;author=G.%20Peluffo&amp;author=H.%20Chen&amp;author=R.%20Gelman&amp;author=S.%20Schnitt&amp;author=K.%20Polyak&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=106&amp;pages=3372-3377&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR16">Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A. 2004, 101: 4966-4971.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1073/pnas.0401064101"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15051869"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC387357"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Reconstruction%20of%20functionally%20normal%20and%20malignant%20human%20breast%20tissues%20in%20mice&amp;author=C.%20Kuperwasser&amp;author=T.%20Chavarria&amp;author=M.%20Wu&amp;author=G.%20Magrane&amp;author=JW.%20Gray&amp;author=L.%20Carey&amp;author=A.%20Richardson&amp;author=RA.%20Weinberg&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=101&amp;pages=4966-4971&amp;publication_year=2004"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR17">Cheng HH, Kuo CC, Yan JL, Chen HL, Lin WC, Wang KH, Tsai KK, GuvÃ©n H, Flaberg E, Szekely L, Klein G, Wu KK: Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan. Proc Natl Acad Sci U S A. 2012, 109: 13231-13236.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1073/pnas.1209919109"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22851770"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421199"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Control%20of%20cyclooxygenase-2%20expression%20and%20tumorigenesis%20by%20endogenous%205-methoxytryptophan&amp;author=HH.%20Cheng&amp;author=CC.%20Kuo&amp;author=JL.%20Yan&amp;author=HL.%20Chen&amp;author=WC.%20Lin&amp;author=KH.%20Wang&amp;author=KK.%20Tsai&amp;author=H.%20Guv%C3%A9n&amp;author=E.%20Flaberg&amp;author=L.%20Szekely&amp;author=G.%20Klein&amp;author=KK.%20Wu&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=109&amp;pages=13231-13236&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR18">Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, et al: HMDB: a knowledge base for the human metabolome. Nucleic Acid Res. 2009, 37: D603-610.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1093/nar/gkn810"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18953024"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=HMDB%3A%20a%20knowledge%20base%20for%20the%20human%20metabolome&amp;author=DS.%20Wishart&amp;author=C.%20Knox&amp;author=AC.%20Guo&amp;author=R.%20Eisner&amp;author=N.%20Young&amp;author=B.%20Gautam&amp;author=DD.%20Hau&amp;author=N.%20Psychogios&amp;author=E.%20Dong&amp;author=S.%20Bouatra&amp;author=R.%20Mandal&amp;author=I.%20Sinelnikov&amp;author=J.%20Xia&amp;author=L.%20Jia&amp;author=JA.%20Cruz&amp;author=E.%20Lim&amp;author=CA.%20Sobsey&amp;author=S.%20Shrivastava&amp;author=P.%20Huang&amp;author=P.%20Liu&amp;author=L.%20Fang&amp;author=J.%20Peng&amp;author=R.%20Fradette&amp;author=D.%20Cheng&amp;author=D.%20Tzur&amp;author=M.%20Clements&amp;author=A.%20Lewis&amp;author=A.%20De%20Souza&amp;author=A.%20Zuniga&amp;author=M.%20Dawe&amp;journal=Nucleic%20Acid%20Res&amp;volume=37&amp;pages=D603-610&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR19">Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012, 149: 1098-1111.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.cell.2012.02.065"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22632973"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586339"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20Skp2-SCF%20E3%20ligase%20regulates%20Akt%20ubiquitination%2C%20glycolysis%2C%20herceptin%20sensitivity%2C%20and%20tumorigenesis&amp;author=CH.%20Chan&amp;author=CF.%20Li&amp;author=WL.%20Yang&amp;author=Y.%20Gao&amp;author=SW.%20Lee&amp;author=Z.%20Feng&amp;author=HY.%20Huang&amp;author=KK.%20Tsai&amp;author=LG.%20Flores&amp;author=Y.%20Shao&amp;author=JD.%20Hazle&amp;author=D.%20Yu&amp;author=W.%20Wei&amp;author=D.%20Sarbassov&amp;author=MC.%20Hung&amp;author=KI.%20Nakayama&amp;author=HK.%20Lin&amp;journal=Cell&amp;volume=149&amp;pages=1098-1111&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR20">Horai H, Arita M, Kanaya S, Nihei Y, Ikeda T, Suwa K, Ojima Y, Tanaka K, Tanaka S, Aoshima K, Oda Y, Kakazu Y, Kusano M, Tohge T, Matsuda F, Sawada Y, Hirai MY, Nakanishi H, Ikeda K, Akimoto N, Maoka T, Takahashi H, Ara T, Sakurai N, Suzuki H, Shibata D, Neumann S, Iida T, Tanaka K, Funatsu K, et al: MassBank: a public repository for sharing mass spectral data for life sciences. J Mass Spectrom. 2010, 45: 703-714.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1002/jms.1777"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20623627"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=MassBank%3A%20a%20public%20repository%20for%20sharing%20mass%20spectral%20data%20for%20life%20sciences&amp;author=H.%20Horai&amp;author=M.%20Arita&amp;author=S.%20Kanaya&amp;author=Y.%20Nihei&amp;author=T.%20Ikeda&amp;author=K.%20Suwa&amp;author=Y.%20Ojima&amp;author=K.%20Tanaka&amp;author=S.%20Tanaka&amp;author=K.%20Aoshima&amp;author=Y.%20Oda&amp;author=Y.%20Kakazu&amp;author=M.%20Kusano&amp;author=T.%20Tohge&amp;author=F.%20Matsuda&amp;author=Y.%20Sawada&amp;author=MY.%20Hirai&amp;author=H.%20Nakanishi&amp;author=K.%20Ikeda&amp;author=N.%20Akimoto&amp;author=T.%20Maoka&amp;author=H.%20Takahashi&amp;author=T.%20Ara&amp;author=N.%20Sakurai&amp;author=H.%20Suzuki&amp;author=D.%20Shibata&amp;author=S.%20Neumann&amp;author=T.%20Iida&amp;author=K.%20Tanaka&amp;author=K.%20Funatsu&amp;journal=J%20Mass%20Spectrom&amp;volume=45&amp;pages=703-714&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR21">Soichot M, Hennart B, Al Saabi A, Leloire A, Froguel P, Levy-Marchal C, Poulain-Godefroy O, Allorge D: Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene. PLoS One. 2011, 6: e25470-<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1371/journal.pone.0025470"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21980470"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181322"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Identification%20of%20a%20variable%20number%20of%20tandem%20repeats%20polymorphism%20and%20characterization%20of%20LEF-1%20response%20elements%20in%20the%20promoter%20of%20the%20IDO1%20gene&amp;author=M.%20Soichot&amp;author=B.%20Hennart&amp;author=A.%20Al%20Saabi&amp;author=A.%20Leloire&amp;author=P.%20Froguel&amp;author=C.%20Levy-Marchal&amp;author=O.%20Poulain-Godefroy&amp;author=D.%20Allorge&amp;journal=PLoS%20One&amp;volume=6&amp;pages=e25470&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR22">Decker T, Kovarik P, Meinke A: GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res. 1997, 17: 121-134.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1089/jir.1997.17.121"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9085936"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=GAS%20elements%3A%20a%20few%20nucleotides%20with%20a%20major%20impact%20on%20cytokine-induced%20gene%20expression&amp;author=T.%20Decker&amp;author=P.%20Kovarik&amp;author=A.%20Meinke&amp;journal=J%20Interferon%20Cytokine%20Res&amp;volume=17&amp;pages=121-134&amp;publication_year=1997"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR23">Du MX, Sotero-Esteva WD, Taylor MW: Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J Interferon Cytokine Res. 2000, 20: 133-142.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1089/107999000312531"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10714548"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Analysis%20of%20transcription%20factors%20regulating%20induction%20of%20indoleamine%202%2C3-dioxygenase%20by%20IFN-gamma&amp;author=MX.%20Du&amp;author=WD.%20Sotero-Esteva&amp;author=MW.%20Taylor&amp;journal=J%20Interferon%20Cytokine%20Res&amp;volume=20&amp;pages=133-142&amp;publication_year=2000"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR24">Sumpter TL, Dangi A, Matta BM, Huang C, Stolz DB, Vodovotz Y, Thomson AW, Gandhi CR: Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO. J Immunol. 2012, 189: 3848-3858.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.4049/jimmunol.1200819"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22962681"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466356"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Hepatic%20stellate%20cells%20undermine%20the%20allostimulatory%20function%20of%20liver%20myeloid%20dendritic%20cells%20via%20STAT3-dependent%20induction%20of%20IDO&amp;author=TL.%20Sumpter&amp;author=A.%20Dangi&amp;author=BM.%20Matta&amp;author=C.%20Huang&amp;author=DB.%20Stolz&amp;author=Y.%20Vodovotz&amp;author=AW.%20Thomson&amp;author=CR.%20Gandhi&amp;journal=J%20Immunol&amp;volume=189&amp;pages=3848-3858&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR25">Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M: An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011, 478: 197-203.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/nature10491"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21976023"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=An%20endogenous%20tumour-promoting%20ligand%20of%20the%20human%20aryl%20hydrocarbon%20receptor&amp;author=CA.%20Opitz&amp;author=UM.%20Litzenburger&amp;author=F.%20Sahm&amp;author=M.%20Ott&amp;author=I.%20Tritschler&amp;author=S.%20Trump&amp;author=T.%20Schumacher&amp;author=L.%20Jestaedt&amp;author=D.%20Schrenk&amp;author=M.%20Weller&amp;author=M.%20Jugold&amp;author=GJ.%20Guillemin&amp;author=CL.%20Miller&amp;author=C.%20Lutz&amp;author=B.%20Radlwimmer&amp;author=I.%20Lehmann&amp;author=A.%20von%20Deimling&amp;author=W.%20Wick&amp;author=M.%20Platten&amp;journal=Nature&amp;volume=478&amp;pages=197-203&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR26">Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, Kouzmenko A, Nohara K, Chiba T, Fujii-Kuriyama Y, Kato S: Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature. 2007, 446: 562-566.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/nature05683"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17392787"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Dioxin%20receptor%20is%20a%20ligand-dependent%20E3%20ubiquitin%20ligase&amp;author=F.%20Ohtake&amp;author=A.%20Baba&amp;author=I.%20Takada&amp;author=M.%20Okada&amp;author=K.%20Iwasaki&amp;author=H.%20Miki&amp;author=S.%20Takahashi&amp;author=A.%20Kouzmenko&amp;author=K.%20Nohara&amp;author=T.%20Chiba&amp;author=Y.%20Fujii-Kuriyama&amp;author=S.%20Kato&amp;journal=Nature&amp;volume=446&amp;pages=562-566&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR27">Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH: Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer. 2009, 9: 231-<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1186/1471-2407-9-231"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19604349"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723126"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Simultaneous%20Foxp3%20and%20IDO%20expression%20is%20associated%20with%20sentinel%20lymph%20node%20metastases%20in%20breast%20cancer&amp;author=AS.%20Mansfield&amp;author=PS.%20Heikkila&amp;author=AT.%20Vaara&amp;author=KA.%20von%20Smitten&amp;author=JM.%20Vakkila&amp;author=MH.%20Leidenius&amp;journal=BMC%20Cancer&amp;volume=9&amp;pages=231&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR28">Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med. 2002, 196: 459-468.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1084/jem.20020121"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12186838"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2196046"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Tryptophan-derived%20catabolites%20are%20responsible%20for%20inhibition%20of%20T%20and%20natural%20killer%20cell%20proliferation%20induced%20by%20indoleamine%202%2C%203-dioxygenase&amp;author=G.%20Frumento&amp;author=R.%20Rotondo&amp;author=M.%20Tonetti&amp;author=G.%20Damonte&amp;author=U.%20Benatti&amp;author=GB.%20Ferrara&amp;journal=J%20Exp%20Med&amp;volume=196&amp;pages=459-468&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR29">Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005, 11: 312-319.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/nm1196"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15711557"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Inhibition%20of%20indoleamine%202%2C%203-dioxygenase%2C%20an%20immunoregulatory%20target%20of%20the%20cancer%20suppression%20gene%20Bin1%2C%20potentiates%20cancer%20chemotherapy&amp;author=AJ.%20Muller&amp;author=JB.%20DuHadaway&amp;author=PS.%20Donover&amp;author=E.%20Sutanto-Ward&amp;author=GC.%20Prendergast&amp;journal=Nat%20Med&amp;volume=11&amp;pages=312-319&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR30">Yasui H, Takai K, Yoshida R, Hayaishi O: Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci U S A. 1986, 83: 6622-6626.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1073/pnas.83.17.6622"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2428037"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC386556"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Interferon%20enhances%20tryptophan%20metabolism%20by%20inducing%20pulmonary%20indoleamine%202%2C3-dioxygenase%3A%20its%20possible%20occurrence%20in%20cancer%20patients&amp;author=H.%20Yasui&amp;author=K.%20Takai&amp;author=R.%20Yoshida&amp;author=O.%20Hayaishi&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=83&amp;pages=6622-6626&amp;publication_year=1986"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR31">Pan MR, Hou MF, Chang HC, Hung WC: Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem. 2008, 283: 11155-11163.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1074/jbc.M710038200"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18319253"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cyclooxygenase-2%20up-regulates%20CCR7%20via%20EP2%2FEP4%20receptor%20signaling%20pathways%20to%20enhance%20lymphatic%20invasion%20of%20breast%20cancer%20cells&amp;author=MR.%20Pan&amp;author=MF.%20Hou&amp;author=HC.%20Chang&amp;author=WC.%20Hung&amp;journal=J%20Biol%20Chem&amp;volume=283&amp;pages=11155-11163&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR32">Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW: Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010, 207: 339-344.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1084/jem.20092506"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20142433"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822606"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cancer-associated%20metabolite%202-hydroxyglutarate%20accumulates%20in%20acute%20myelogenous%20leukemia%20with%20isocitrate%20dehydrogenase%201%20and%202%20mutations&amp;author=S.%20Gross&amp;author=RA.%20Cairns&amp;author=MD.%20Minden&amp;author=EM.%20Driggers&amp;author=MA.%20Bittinger&amp;author=HG.%20Jang&amp;author=M.%20Sasaki&amp;author=S.%20Jin&amp;author=DP.%20Schenkein&amp;author=SM.%20Su&amp;author=L.%20Dang&amp;author=VR.%20Fantin&amp;author=TW.%20Mak&amp;journal=J%20Exp%20Med&amp;volume=207&amp;pages=339-344&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR33">Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010, 17: 225-234.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.01.020"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20171147"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849316"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20common%20feature%20of%20leukemia-associated%20IDH1%20and%20IDH2%20mutations%20is%20a%20neomorphic%20enzyme%20activity%20converting%20alpha-ketoglutarate%20to%202-hydroxyglutarate&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=DR.%20Wise&amp;author=O.%20Abdel-Wahab&amp;author=BD.%20Bennett&amp;author=HA.%20Coller&amp;author=JR.%20Cross&amp;author=VR.%20Fantin&amp;author=CV.%20Hedvat&amp;author=AE.%20Perl&amp;author=JD.%20Rabinowitz&amp;author=M.%20Carroll&amp;author=SM.%20Su&amp;author=KA.%20Sharp&amp;author=RL.%20Levine&amp;author=CB.%20Thompson&amp;journal=Cancer%20Cell&amp;volume=17&amp;pages=225-234&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR34">Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010, 18: 553-567.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.11.015"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21130701"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105845"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Leukemic%20IDH1%20and%20IDH2%20mutations%20result%20in%20a%20hypermethylation%20phenotype%2C%20disrupt%20TET2%20function%2C%20and%20impair%20hematopoietic%20differentiation&amp;author=ME.%20Figueroa&amp;author=O.%20Abdel-Wahab&amp;author=C.%20Lu&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=A.%20Shih&amp;author=Y.%20Li&amp;author=N.%20Bhagwat&amp;author=A.%20Vasanthakumar&amp;author=HF.%20Fernandez&amp;author=MS.%20Tallman&amp;author=Z.%20Sun&amp;author=K.%20Wolniak&amp;author=JK.%20Peeters&amp;author=W.%20Liu&amp;author=SE.%20Choe&amp;author=VR.%20Fantin&amp;author=E.%20Paietta&amp;author=B.%20Lowenberg&amp;author=JD.%20Licht&amp;author=LA.%20Godley&amp;author=R.%20Delwel&amp;author=PJ.%20Valk&amp;author=CB.%20Thompson&amp;author=RL.%20Levine&amp;author=A.%20Melnick&amp;journal=Cancer%20Cell&amp;volume=18&amp;pages=553-567&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR35">Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011, 19: 17-30.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.12.014"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21251613"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229304"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Oncometabolite%202-hydroxyglutarate%20is%20a%20competitive%20inhibitor%20of%20alpha-ketoglutarate-dependent%20dioxygenases&amp;author=W.%20Xu&amp;author=H.%20Yang&amp;author=Y.%20Liu&amp;author=Y.%20Yang&amp;author=P.%20Wang&amp;author=SH.%20Kim&amp;author=S.%20Ito&amp;author=C.%20Yang&amp;author=P.%20Wang&amp;author=MT.%20Xiao&amp;author=LX.%20Liu&amp;author=WQ.%20Jiang&amp;author=J.%20Liu&amp;author=JY.%20Zhang&amp;author=B.%20Wang&amp;author=S.%20Frye&amp;author=Y.%20Zhang&amp;author=YH.%20Xu&amp;author=QY.%20Lei&amp;author=KL.%20Guan&amp;author=SM.%20Zhao&amp;author=Y.%20Xiong&amp;journal=Cancer%20Cell&amp;volume=19&amp;pages=17-30&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR36">Platten M, Wick W, Van den Eynde BJ: Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012, 72: 5435-5440.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1158/0008-5472.CAN-12-0569"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23090118"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Tryptophan%20catabolism%20in%20cancer%3A%20beyond%20IDO%20and%20tryptophan%20depletion&amp;author=M.%20Platten&amp;author=W.%20Wick&amp;author=BJ.%20Van%20den%20Eynde&amp;journal=Cancer%20Res&amp;volume=72&amp;pages=5435-5440&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR37">West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M: Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005, 3: e187-<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1371/journal.pbio.0030187"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15869330"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088973"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Determination%20of%20stromal%20signatures%20in%20breast%20carcinoma&amp;author=RB.%20West&amp;author=DS.%20Nuyten&amp;author=S.%20Subramanian&amp;author=TO.%20Nielsen&amp;author=CL.%20Corless&amp;author=BP.%20Rubin&amp;author=K.%20Montgomery&amp;author=S.%20Zhu&amp;author=R.%20Patel&amp;author=T.%20Hernandez-Boussard&amp;author=JR.%20Goldblum&amp;author=PO.%20Brown&amp;author=M.%20van%20de%20Vijver&amp;author=M.%20van%20de%20Rijn&amp;journal=PLoS%20Biol&amp;volume=3&amp;pages=e187&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR38">Chen JL, Espinosa I, Lin AY, Liao OY, van de Rijn M, West RB: Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res. 2013, 19: 5127-5135.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1158/1078-0432.CCR-12-3127"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23804424"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778157"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Stromal%20responses%20among%20common%20carcinomas%20correlated%20with%20clinicopathologic%20features&amp;author=JL.%20Chen&amp;author=I.%20Espinosa&amp;author=AY.%20Lin&amp;author=OY.%20Liao&amp;author=M.%20van%20de%20Rijn&amp;author=RB.%20West&amp;journal=Clin%20Cancer%20Res&amp;volume=19&amp;pages=5127-5135&amp;publication_year=2013"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR39">Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP: Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther. 2008, 7: 1212-1225.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.4161/cbt.7.8.6220"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18458534"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Human%20breast%20cancer-associated%20fibroblasts%20%28CAFs%29%20show%20caveolin-1%20downregulation%20and%20RB%20tumor%20suppressor%20functional%20inactivation%3A%20implications%20for%20the%20response%20to%20hormonal%20therapy&amp;author=I.%20Mercier&amp;author=MC.%20Casimiro&amp;author=C.%20Wang&amp;author=AL.%20Rosenberg&amp;author=J.%20Quong&amp;author=A.%20Minkeu&amp;author=KG.%20Allen&amp;author=C.%20Danilo&amp;author=F.%20Sotgia&amp;author=G.%20Bonuccelli&amp;author=JF.%20Jasmin&amp;author=H.%20Xu&amp;author=E.%20Bosco&amp;author=B.%20Aronow&amp;author=A.%20Witkiewicz&amp;author=RG.%20Pestell&amp;author=ES.%20Knudsen&amp;author=MP.%20Lisanti&amp;journal=Cancer%20Biol%20Ther&amp;volume=7&amp;pages=1212-1225&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR40">Erez N, Truitt M, Olson P, Arron ST, Hanahan D: Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010, 17: 135-147.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2009.12.041"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20138012"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cancer-associated%20fibroblasts%20are%20activated%20in%20incipient%20neoplasia%20to%20orchestrate%20tumor-promoting%20inflammation%20in%20an%20NF-kappaB-dependent%20manner&amp;author=N.%20Erez&amp;author=M.%20Truitt&amp;author=P.%20Olson&amp;author=ST.%20Arron&amp;author=D.%20Hanahan&amp;journal=Cancer%20Cell&amp;volume=17&amp;pages=135-147&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li></ol></div></section><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="CopyrightMessage"><h2 class="Heading js-ToggleCollapseSection">Copyright</h2><div class="js-CollapseSection"><div xmlns="http://www.w3.org/1999/xhtml" class="ArticleCopyright">Â©&nbsp;Chen et al.; licensee BioMed Central; licensee BioMed Central Ltd.&nbsp;2014<div class="CopyrightComment">
                <p xmlns="" class="SimplePara">This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/licenses/by/4.0"><span class="RefSource">http://creativecommons.org/licenses/by/4.0</span></a></span>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/publicdomain/zero/1.0/"><span class="RefSource">http://creativecommons.org/publicdomain/zero/1.0/</span></a></span>) applies to the data made available in this article, unless otherwise stated.</p>
              </div></div></div></section></div>
                            


                        </div>
                    </div>
                    <div class="layout__sidebar-right" id="main-sidebar">
                        
                        <div class="block">
                            <aside role="complementary">
                                <div class="SideBox">
                                    
    <p class="SideBox_action">
        <a class="SideBox_pdf" id="articlePdf" target="_blank" href="/track/pdf/10.1186/s13058-014-0410-1?site&#x3D;breast-cancer-research.biomedcentral.com" data-track-event="click" data-event-category="PDF Download"
           data-event-action="Click download article PDF"
           data-event-label="10.1186/s13058-014-0410-1">Download PDF</a>
    </p>

                                    
                                    
    <h3 class="export-citations-button" data-toggle="collapse" data-target="js-exportCitations">Export citations</h3>
    <div id="js-exportCitations" class="export-citations-content panel">
        <div class="panel__section">
            <h4 class="panel__title">Citations & References</h4>
            <ul class="ListDownload" id="articleReferences">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks citations and references"
                       data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=refman&flavour=full">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote citations and references" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=endnote&flavour=full">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef citations and references" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=bibtex&flavour=full">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">Article citation</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks article citations" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=refman&flavour=citation">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote article citations" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=endnote&flavour=citation">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef article citations" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=bibtex&flavour=citation">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">References</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks references" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=refman&flavour=references">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote references" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=endnote&flavour=references">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef references" data-event-label="10.1186/s13058-014-0410-1"
                       href="http://citation-needed.springer.com/v2/references/10.1186/s13058-014-0410-1?format=bibtex&flavour=references">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
    </div>

                                </div>
                                <div class="SideBox">
                                    <nav xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="ArticleNavigation" class="table-of-contents" aria-label="table of contents"><div class="table-of-contents__content" data-sticky="toc"><h3 class="table-of-contents__title is-open" data-toggle="collapse" data-target="tocMenu" data-event-category="Table of Contents" data-track-event="click" data-event-action="Toggle ToC" data-event-label="Toggle" data-toggle-disable-clickoff="true" aria-expanded="true">Table of Contents</h3><ul class="table-of-contents__menu is-open" role="menu" id="tocMenu" aria-expanded="true"><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Abs1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Abstract">Abstract</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Background">Background</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec2" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Methods">Methods</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec14" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Results">Results</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec21" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Discussion">Discussion</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec22" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Conclusion">Conclusion</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec23" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Additional files">Additional files</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Declarations" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Declarations">
                        Declarations
                      </a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Bib1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="References">References</a></li><li role="menuitem" class="table-of-contents__item is-hidden"><a class="table-of-contents__link" href="#comments" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Comments">Comments</a></li></ul></div></nav>
                                </div>
                                <div class="SideBox">
                                    <h3 class="SideBox_title">Metrics</h3>
                                    <ul class="SideBox_list list-stacked list-stacked--small list-stacked--2">
                                        <div id="article-access-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/access-count/10.1186/s13058-014-0410-1 #accessCount-container"></div>
                                        <div id="citation-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/citation-count/10.1186/s13058-014-0410-1 #count-container"></div>
                                        <div id="altmetric-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/altmetric/10.1186/s13058-014-0410-1 #altmetric-container"></div>
                                    </ul>
                                </div>
                                
    <div id="sociaMediaShare" class="SideBox">
        <h3 class="SideBox_title">Share this article</h3>
        <ul id="shareButtons" class="share">
            <li class="share__item">
                <button id="shareOnTwitter" class="js-btnShareOnTwitter share__button share__button--twitter" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Twitter" data-event-label="10.1186/s13058-014-0410-1">
                    <span class="sr-only">Share on Twitter</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnFacebook" class="js-btnShareOnFacebook share__button share__button--facebook" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Facebook" data-event-label="10.1186/s13058-014-0410-1">
                    <span class="sr-only">Share on Facebook</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnLinkedIn" class="js-btnShareOnLinkedIn share__button share__button--linkedin" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share LinkedIn" data-event-label="10.1186/s13058-014-0410-1">
                    <span class="sr-only">Share on LinkedIn</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnWeibo" class="js-btnShareOnWeibo share__button share__button--weibo" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Weibo" data-event-label="10.1186/s13058-014-0410-1">
                    <span class="sr-only">Share on Weibo</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnGooglePlus" class="js-btnShareOnGplus share__button share__button--gplus" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Google+" data-event-label="10.1186/s13058-014-0410-1">
                    <span class="sr-only">Share on Google Plus</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnReddit" class="js-btnShareOnReddit share__button share__button--reddit" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Reddit" data-event-label="10.1186/s13058-014-0410-1">
                    <span class="sr-only">Share on Reddit</span>
                </button>
            </li>
        </ul>
    </div>

                                
    
    <div class="SideBox">
        <h3 class="SideBox_title">See updates</h3>
        <a data-crossmark="10.1186/s13058-014-0410-1" rel="modal:open" href="#crossmark-dialog" data-track-event="click" data-event-category="Article Page" data-event-action="Click CrossMark" data-event-label="10.1186/s13058-014-0410-1">
            <img class="CrossMark" id="crossmark-icon" src="/static/images/crossmark-c0483e404d.png" alt="Click to get updates and verify authenticity" />
        </a>
        <div id="crossmark-dialog" class="u-isHidden">
            <iframe id="crossmark-iframe" frameborder="0" width="550" height="550"></iframe>
        </div>
        <div class="Modal" data-modal="wrap">
            <div class="Modal_inner">
                <a rel="modal:close" id="close-10.1186/s13058-014-0410-1" class="Icon Icon--cross-default"></a>
                <div class="Modal_content" data-modal="content"></div>
            </div>
        </div>
    </div>
    

                                
    

                                
    

                                <div class="SideBox">
                                    <h3 class="SideBox_title">Other Actions</h3>
                                    <ul class="list-stacked list-stacked--2 list-stacked--small">
                                        <li class="list-stacked__item">
                                            
    <a data-track-event="click" data-event-category="Article Page" data-event-action="Order article reprints" data-event-label="10.1186/s13058-014-0410-1" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186%2Fs13058-014-0410-1&volume=16&issue=4&title=Cancer%2Fstroma+interplay+via+cyclooxygenase-2+and+indoleamine+2%2C3-dioxygenase+promotes+breast+cancer+progression&author_name=Jing-Yi+Chen&start_page=1&end_page=14">Order reprint</a>

                                        </li>
                                    </ul>
                                </div>
                                
        
        <div id="sociaMediaAccounts" class="SideBox">
            <h3 class="SideBox_title">Follow</h3>
            <ul class="follow follow--inline">
                
                <li class="follow__item">
                    <a class="follow__link follow__link--twitter-2" href="https://twitter.com/BCRJournal" data-track-event="click" data-event-category="Social Media"
                       data-event-action="Click Follow Social Media" data-event-label="Twitter">
                        <span class="follow__label">Follow us on Twitter</span>
                    </a>
                </li>
                

                

                
            </ul>
        </div>
        
    
                            </aside>
                            
    <div id="FulltextAd" class="adsbox Ad Ad--skyscraper">
        <div class="Ad_content">
            <p class="Ad_label">Advertisement</p>
            <span id="pbgrd-43415139"></span>
        </div>
    </div>

                        </div>
                    </div>
                </div>
            </div>
        </main>
        
            <div class="journal-footer">
                <div class="journal-footer__inner">
                    <div class="journal-footer__summary">
                        <h4 class="journal-footer__title">
                            
                            <span class="journal-footer__title-text">Breast Cancer Research</span>
                        </h4>
                        <p class="journal-footer__issn">ISSN: 1465-542X</p>
                    </div>
                    
                        <div class="journal-footer__contact">
                            <h4 class="journal-footer__contact-title">Contact us</h4>
                            <ul class="journal-footer__contact-list">
                                
                                    <li class="journal-footer__contact-item">Editorial email: <a href="mailto:editorial@breast-cancer-research.com">editorial@breast-cancer-research.com</a></li>
                                
                                
                                    <li class="journal-footer__contact-item">Support email: <a href="mailto:info@breast-cancer-research.com">info@breast-cancer-research.com</a></li>
                                
                            </ul>
                        </div>
                    
                </div>
            </div>
        
         
    <footer>
        <div class="footer">
            <div class="footer__header">
                <img srcset="/static/images/biomed-central-logo-white-3c6c941205.svg" src="/static/images/biomed-central-logo-white-faac4202d5.png" class="logo__img footer__logo" alt="Biomed Central" />
                
                    <h2 class="footer__menu-title">Publisher Main Menu</h2>
                    <ul class="footer__primary-menu">
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/journals">Explore journals</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/getpublished">Get published</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/about">About BioMed Central</a>
                            </li>
                        
                    </ul>
                
            </div>
            <div id="Test-FooterExists" class="footer__content">
                <div class="footer__legal">
                    
                    <p class="footer__terms">By continuing to use this website, you agree to our <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/terms-and-conditions">Terms and Conditions</a>, <a class="footer__link footer__link--inline"
                                                                                                                                                                                                                               href="//www.biomedcentral.com/terms-and-conditions/privacy-statement">Privacy
                        statement</a> and <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/cookies">Cookies</a> policy.</p>
                </div>
                
    <nav id="publisherFooter" class="footer__nav">
        <h3 class="footer__menu-title">Publisher secondary menu</h3>
        <div class="footer__nav-inner">
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://blogs.biomedcentral.com/">Read more on our blogs</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/login">Receive BMC newsletters</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/account">Manage article alerts</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/language-editing/">Language editing for authors</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/scientific-editing/">Scientific editing for authors</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/policies">Policies</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/accessibility">Accessibility</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/press-centre">Press center</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/contact-us">Contact us</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="https://biomedcentral.typeform.com/to/VLXboo">Leave feedback</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/jobs">Careers</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu footer__menu--follow">
                <div class="footer__follow">
                    <h3 class="footer__follow-title">Follow BioMed Central</h3>
                    <ul class="follow follow--inline">
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--twitter" href="https://twitter.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Twitter">
                                <span class="follow__label">Twitter</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--facebook" href="https://www.facebook.com/BioMedCentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Facebook">
                                <span class="follow__label">Facebook</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--gplus" href="https://plus.google.com/106226337984152901734/" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Google Plus">
                                <span class="follow__label">Google Plus</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--weibo" href="http://www.weibo.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Weibo">
                                <span class="follow__label">Weibo</span>
                            </a>
                        </li>
                    
                    </ul>
                </div>
            </div>
        </div>
    </nav>


            </div>
        </div>
        <div class="branding-bar">
            <div class="logo branding-bar__logo">
                <img srcset="/static/images/logo-springernature-4230d19d5c.svg" src="/static/images/logo-springernature-828f4f84c8.png" class="logo__img branding-bar-logo__img" alt="Springer Nature Logo" />
            </div>
            <p class="branding-bar__copyright">&#169; 2017 BioMed Central Ltd unless otherwise stated. Part of <a class="branding-bar__link" href="http://www.springernature.com">Springer Nature</a>.</p>
        </div>
    </footer>
    <noscript class="js-cookie-banner-noscript">
        <div class="cookie-banner js-cookie-banner">
            <div class="cookie-banner__inner">
                <p class="cookie-banner__message">
                    We use cookies to improve your experience with our site.
                    <a href="https://www.biomedcentral.com/cookies"
                       class="cookie-banner__link"
                       data-track-event="click"
                       data-event-category="EU Cookie Law Banner"
                       data-event-action="Find out more">More information <span class="sr-only">about our cookie policy</span>
                    </a>
                </p>
                <button hidden class="cookie-banner__dismiss js-cookie-banner-dismiss"
                        data-track-event="click"
                        data-event-category="EU Cookie Law Banner"
                        data-event-action="Close"><span class="cookie-banner__dismiss-text">Close</span>
                </button>
            </div>
        </div>
</noscript>


    </div>
    
    <img class='tracker' style='display:none' src='/track/article/10.1186/s13058-014-0410-1' alt=""/>

    <div id="JFulltext"></div>

    
    <script type="text/javascript" src="//cdn.pbgrd.com/bmc.js" async="async"></script>

    

    
<script>
(function() {
    var linkEl = document.querySelector('.js-ctm');
    if (linkEl && window.matchMedia && window.matchMedia(linkEl.media)) {
        var vendorScript = document.createElement('script');
        vendorScript.src = '/static/js/oscar-vendor-67103b4f35.js';
        vendorScript.async = false;
        document.body.appendChild(vendorScript);
        var appScript = document.createElement('script');
        appScript.src = '/static/js/oscar-app-4e91ea0ef9.js';
        appScript.async = false;
        document.body.appendChild(appScript);
    }
})();
</script>



<script type="text/javascript">
    if (config) {
        (function (d) {
            Array.prototype.forEach.call(d.getElementsByClassName('RealMediaAd'), function (adElement) {
                var iframe = d.createElement('iframe');
                iframe.frameBorder = '0';
                iframe.scrolling = 'no';
                var position = adElement.getAttribute("data-position"),
                        iframeInDoc = adElement.getElementsByClassName('Ad_content')[0].appendChild(iframe),
                        doc = iframeInDoc.contentWindow.document;

                doc.open().write('<body onload="window.location.href = '
                        + '\'/placeholder/v1/advertising/realMedia?siteWithPath=' + encodeURIComponent(config.siteWithPath)
                        + '&placement=' + position + '\';">');
                doc.close();
            });
        })(document);
    }
</script>



    
        <script type="text/javascript">
            document.addEventListener('readystatechange', function () {
                if (document.readyState === 'complete') {
                    setTimeout(function () {
                        var script = document.createElement("script");
                        script.type = "text/javascript";
                        script.src = "https://recommendations.springernature.com/latest/entry-point.js";
                        document.getElementsByTagName("head")[0].appendChild(script);
                    }, 0);
                }
            });
        </script>
    


    <script type="text/javascript">
        var _kiq = _kiq || [];
        (function () {
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/9CC.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/aC6.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
        })();
    </script>


<noscript>
	<img hidden src="https://verify.nature.com/verify/nature.png" border="0" width="0" height="0" style="display: none">
</noscript>
</body>
</html>

